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Summary
HGF/SF-c-mc^ is involved in stromal-epithelial regulation o f cellular processes such as 
growth, dissociation, motility and invasiveness in epithelial cells and angiogenesis 
in endothelial cells^ "^ .^ When coordinated they appear to play an important role in the 
morphogenesis o f epithelial tissues There is increasing evidence that HGVI^V-c-met 
is an essential regulating component o f breast duct development 276,334
expression o f HGF/SF-c-me? may therefore be involved in biological mechanisms that 
promote invasion and metastasis in human cancers Loss o f heterozygosity (LOH) at 
the c-met locus in breast cancer patients has been associated with disease-relapse and 
reduced survival
The aims o f this thesis were:
1. To investigate the frequency and significance o f LOH o f c-met in patients with
breast cancer.
2. To investigate HGF/SF and c-met expression in patients with breast cancer.
3. To investigate the relationship o f HGF/SF to tumour proliferation and
angiogenesis in patients with breast cancer.
Investigation on frequency o f  loss o f  heterozvgositv o f  the c-met proto-oncogene in 
human breast cancer
Aberrant HGF/SF-c-we^ function in breast cancer was first suggested by the observation 
o f a high frequency o f LOH at 7q31 (the c-met locus) in human breast cancer patients 
In this study we examined blood DNA derived from 111 patients with primary breast
15
cancer using the pMet H probe by Southern blotting. O f the 111 patients, 52 patients 
were heterozygous for the Taq 1 restriction fragment length polymorphism (RFLP) o f  
7.5 and 4.0 kb. Tumour DNA from these patients were then analysed for LOH at 7q31. 
Complete LOH at 7q31 was observed in 4% o f cases only. The results o f this study 
failed to confirm the reported high frequency o f  LOH o f  c-met and do not support the 
presence o f a tumour suppressor gene at 7q31 in human breast cancer.
HGF/SF-c-me^ ligand receptor system in human breast cancer
In this study a statistical association between HGF/SF and c-met in relation to disease- 
relapse in patients with primary breast cancer was demonstrated. Furthermore, the data 
confirm the presence o f increased HGF/SF levels in human breast cancer when 
compared to tumour-free breast tissue. HGF/SF levels demonstrated statistically 
significant associations with disease-relapse and death. These findings concord with 
three similar studies protein was observed in all samples o f  tumour-free
breast tissue and in a proportion o f patients with breast cancer. Patients with detectable 
c-met demonstrated a significant association with disease relapse. This pattern o f  
receptor expression and relationship to disease progression has subsequently been 
confirmed These observations provide strong support to the hypothesis that aberrant 
HGF/SF-c-mc^ expression occurs in breast cancer.
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HGF/SF. angiogenesis and tumour cell proliferation in primary breast cancer
In this study, a significant correlation between HGF/SF levels and tumour angiogenesis 
was observed in patients with breast cancer. Further evidence o f  a link between HGF/SF 
and tumour angiogenesis is provided by the observation o f a direct relationship between 
HGF/SF and the endothelial cell marker, von Willebrand's factor, in breast cancer 
Also in this study, HGF/SF levels significantly correlated with KI-67 index and 
therefore tumour proliferation. HGF/SF is known to promote breast epithelial cell 
growth in vitro However, HGF/SF promotion o f breast cancer in vivo appears
to be related to angiogenesis rather than direct stimulation o f cellular proliferation .
Conclusions
The results o f this thesis support the hypothesis that aberrant HGF/SF-c-mel expression 
occurs in human breast cancer and is related to disease progression. HGF/SF expression 
in breast cancer is related to both angiogenesis and tumour proliferation. The 
involvement o f  a tumour suppressor gene at the c-met locus is not confirmed.
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Chapter 1 : Introduction and Proposal for Thesis
Breast cancer is common, affecting one in 12 women and causes 21,000 deaths per 
annum in the UK The majority o f these deaths will be due to metastatic disease. The 
metastatic pathway involves processes such as tumour cell separation, proteolysis o f  
extracellular matrix (ECM), occupation o f  cleared ECM due to increased cell motility, 
and angiogenesis In developing organ systems, organised invasive growth o f  
epithelium into stromal tissue is often dependent upon the inductive effect o f  
mesenchyme. Parallels are therefore often made between epithelial-mesenchymal 
interactions during development and during carcinogenesis Factors that regulate 
these interactions may therefore be o f importance in the biology, prognosis and 
treatment o f breast cancer.
Molecular bioloev o f mammarv gland development
The initial development o f  the mammary gland involves both an interaction between an 
epithelial rudiment at the nipple and the underlying mesenchyme and a response to 
maternal hormones o f pregnancy and lactation At birth, a primitive epithelial duct 
with few side branches has developed embedded in the mesenchymal fat pad. During 
puberty, ductal elongation and branching morphogenesis occur. The final stage o f breast 
development, lobuloalveolar differentiation, occurs during pregnancy where multiple 
alveoli bud from ducts to form the milk secretory units. Development o f the normal 
breast is regulated by endocrine hormonal action. Such hormones exert their effects
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through local production o f growth factors that interact in an autocrine or paracrine 
fashion. The hormonal regulation o f breast development is summarised (Table 1.1). 
Inductive interactions between epithelium and mesenchyme are essential for growth and 
differentiation o f the mammary gland during embryogenesis and throughout postnatal 
life (Figure 1.1). Branching morphogenesis is an important stage in the development o f  
different epithelial organs and the adjacent mesenchyme appears to be o f importance 
The inducing effect o f the mesenchyme is partly due to interactions with the ECM 
Flowever, culture o f mammary gland epithelial cells in collagen gels allows only 
limited growth and branching morphogenesis suggesting additional signals from 
stromal cells are required identity o f soluble factors involved in stromal
epithelial interactions during the development o f the mammary gland are the subject o f  
ongoing investigation. Epithelial tyrosine kinase receptors and their stromal ligands 
may be o f  importance. These ligand-receptor pairs were initially associated with 
mediating mitogenic signals because o f  their transforming potential. However, recent 
studies have demonstrated tyrosine kinase receptors can also regulate differentiation, 
cell movement and morphogenesis pm^hermore, studies o f the development
o f kidney, lung and liver in mice have supported the importance o f mesenchymal 
ligands o f  epithelial tyrosine kinases 20.189,220,222,261,203,265,310
Hepatocyte growth factor/scatter factor (HGF/SF) is a mesenchymal/stromal derived 
cytokine. The tyrosine kinase receptor to HGF/SF, encoded by the c-met proto­
oncogene, is expressed in a wide variety o f human epithelial cell types. Unlike many 
other growth factors such as the epidermal growth factor (EGF) family, transforming
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Table 1.1
Sequence o f regulatory factors in development o f  mammary gland (Dickson et al^ )^.
Stage Systemic factors Local factors
Epithelial bud
(+)T ransplacental 
hormones
Unknown local factors 
Stromal induction
Fat pad penetration
(+) Oestrogen 
(+) Growth hormone
(+?) TGF-a 
(4-) IGF 
(-?) TGF-P
Ductal elongation, branching 
following puberty
(+) Oestrogen 
(+) Growth hormone 
(+) Progesterone 
(+) Prolactin 
(+) Insulin 
(+)Glucocorticoids
(+?) TGF-a 
(+) IGF 
(-?) TGF-P
Lobuloalveolar differentiation
(+) Oestrogen 
(+) Progesterone 
(+) Oxytocin 
(-?) Prolactin
(+?) TGF-a 
(+) EGF 
(+) CSF-1 
(+?) FGF 
(-?) TGF-P
TGF transforming groAVth factor 
IGF insulin-like growth factor 
FGF fibroblast growth factor 
EGF epidermal groAvth factor
CSF colony stimulating factor
\6th w eek
Transplacental horm ones 
Mesenchymal induction
7th w eek
A
6th month
Figure LI
Development o f  human mammaiy gland. The mammary ridges first appear at 4 weeks as 
thickened lines o f  epidermis extending from thorax to thigh. Under the influence o f  
transplacental hormones o f  pregnancy and inductive effect o f  mesenchyme, mammary 
ridge ectoderm proliferates in the 5th week to form primary mammary buds. Secondary 
buds form during the 3rd month and become canalised to form lactiferous ducts during the 
last 4 months o f foetal life. Organisation o f  lactiferous ducts around the developing nipple 
occurs in the 8th month. Factors such as TGF-a, TGF-P and IGF may mediate hormone 
induced signals. The local mediators o f  mesenchymal induction are largely unknown.
growth factor (TGF)-p, fibroblast growth factor (FGF) 1 & 4, HGF/SF appears to act 
principally as paracrine effector o f  normal epithelial cells. There is evidence that 
HGF/SF-c-me^ may play a role in the stromal-epithelial interactions participating in 
morphogenesis. In collagen matrix, HGF/SF induces the formation o f branched tubules 
in Madin-Darby canine kidney (MDCK) epithelial cells Furthermore, HGF/SF
has been shown to induce lumen-like structures in malignant breast epithelial cells in 
culture The role o f HGF/SF and c-met in organ morphogenesis is supported by in- 
situ hybridisation and RNase protection experiments where c-met is detected 
predominantly in epithelial cells o f various developing organs whereas the ligand is 
expressed in adjacent stromal cells Aberrant expression o f this ligand/receptor pair 
may result in cell dissociation, invasion and metastasis. LOH o f c-met in human breast 
cancer patients has been associated with reduced disease-free and overall survival 
Furthermore, high levels o f HGF/SF have been demonstrated in human breast cancer 
extracts The subject o f this thesis is to further investigate HGF/SF and c-met in 
human breast cancer.
Review o f HGF/SF and its receptor, the c-met proto-oncogene product 
Discoverv o f  HGF and scatter factor
HGF was identified as a blood borne polypeptide present in the bloodstream o f  
hepatectomised animals and capable o f stimulating hepatocyte proliferation 2^7,196,255 
1984, Stoker observed that human mammary epithelial cells cultured in fibroblast 
conditioned media appeared as contiguous cell sheets. When grown in media
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conditioned by MRC 5 fibroblasts the cells were dissociated A similar effect with 
MDCK cells suggested that MRC 5 fibroblasts produce an epithelial scatter factor (SF) 
Sequence analysis o f the N-terminal o f  the subunit o f SF revealed it to be the 
corresponding portion o f HGF By a combination o f sequence, immunochemical and 
biological analysis it was established that HGF and SF were identical 25,85,142,319,320 ^he 
high affinity receptor to HGF/SF was subsequently identified as the c-met proto­
oncogene product 23.202
Molecular structure o f HGF/SF
HGF/SF has been fully purified, amino acid sequence determined and cDNA cloned. 
HGF/SF is a single chain peptide o f 728 amino acid residues containing a 29 amino acid 
signal sequence and a 25 amino acid pro-sequence ^^ 2.198,340 gy^thesised and secreted as 
a single chain pro-form HGF/SF needs to be converted to the mature heterodimeric 
form by extracellular cleavage. The mature HGF/SF molecule is a disulphide linked 
heterodimeric protein consisting o f  a 69 kDa heavy a-chain and a 34kDa light (3-chain 
(Figure 1.2) ^^ '^ 27.339 Molecular cloning and recombinant expression o f HGF/SF reveal 
that it is secreted in the monomeric 90kDa form 2^9,252 activity o f HGF/SF
requires the proteolytic hydrolysis o f  an Arg-Val bond within its prosequence by 
enzymes with serine protease activity ^^ ^^ 94,198,203,205,340 enzymes, including
urokinase plasminogen activator, have been shown to activate HGF/SF (Figure 1.2)
77,201 ^i|-hough monomeric HGF/SF binds to its receptor with high affinity, proteolytic 
processing into the heterodimeric form is required for mitogenic and scattering activity
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Pro
Kl K2 K3 K4
a-chain
Ser— ^
Proteolytic 
processing site
Arg Vai
K2 i
p Chain
K3
K4
K1
PyrGlu Ser
a  chain
p chain
Figure 1.2
The mature HGF/SF molecule is a heterodimer consisting o f  a 69 kDa 
a-chain and a 34 kDa p-chain. Enzymatic hydrolysis o f  an arginine- 
valine (Arg-Val) bond within pro-HGF/SF by serine proteases pro­
duces the active heterodimeric form o f  HGF/SF. K1-K4 represent the 
four kringle domains o f  HGF/SF which are involved in receptor 
binding and ligand activity.
77,158,185,193,201 ^he Œ-chaiiï contains 4 kringle domains that are essential for protein- 
protein interactions Mutagenesis and deletional studies have shown that kringles 1 
and 2 are essential for receptor binding, whereas kringles 3 and 4 are needed for 
biological activity The HGF/SF gene has been localised by in-situ hybridisation 
with a 3H-labelled probe to chromosome 7ql 1.2-21 .
Source o f HGF/SF
HGF/SF production has been detected in numerous tissues including fibroblasts, 
endothelial cells, Kupffer cells and lipid-storing cells o f the liver In addition tumour 
cells have been observed to express HGF/SF mRNA or produce HGF/SF protein 
102, 178,256,280,337 HGF/SF concentrations are also elevated in patients with liver
disease and in some cancer patients Tanaguchi et al, observed a decrease in
serum HGF/SF levels following breast cancer surgery suggesting tumour as the primary 
source
HGF/SF is expressed by many organs throughout the body. It has been detected at the
mRNA or protein level in cultured fibroblasts derived from organs such as lung,
stomach, colon, breast, prostate and skin Tissue extraction and
immunohistochemical (IHC) studies initially demonstrated expression in the pancreas,
small intestine, salivary glands, thyroid and brain Further studies confirmed these
findings and also detected strong signals in normal human breast and other tissues 
(Table 1.2) 48.306,328,329
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Table 1.2
Immunoreactivity for HGF/SF in human and rat tissues (W olf et al
Strong Moderate Weak Negative
Human breast Lung Adenohypophysis Parathyroid
Skin Gastrointestinal tract Adrenal cortex Adrenal medulla
Bladder Salivary glands Thyroid Lymphocytes
Mésothélium Exocrine pancreas Testis Myocytes
Prostate and seminal Biliary tree Proximal renal tubules Glial cells
vesicles
Distal renal tubules Uterus and fallopian 
tubes
Collecting ducts Endothelium
Syncitiotrophoblast Macrophages
Extravillous trophoblast
Large neurones
Megakaryocytes
Granulocytes
Autocrine and paracrine action o f HGF/SF
There has been extensive investigation into whether HGF/SF exerts its function by 
autocrine or paracrine pathways. Studies both in vitro and in vivo suggest that HGF/SF 
is a mesenchymal/stromal derived cytokine serving as a paracrine effector o f stromal- 
epithelial interactions. HGF/SF production in vitro appears to be restricted to 
predominantly fibroblast and not epithelial cell lines Other mesenchymal cells have 
been reported to produce HGF/SF, for example; Kupffer cells, endothelial cells, lipid- 
storing cells in the liver, endothelial cells in the lung, mammary adipocytes and HL-60 
myelo-monocytic cells 210,230,233,271.280 development, HGF/SF is expressed in
distinct mesenchymal embryonic tissues lying in close proximity to c~met expressing 
epithelium, suggesting a paracrine mode o f interaction Furthermore, the HGF/SF 
gene promoter is active in mesenchymal but not epithelial cells supporting a paracrine 
model o f  stromal-epithelial interaction
Studies on certain cancer cell lines suggest that HGF/SF and c-met may also interact in 
an autocrine fashion The gastric cancer cell line MKN 45 expresses both HGF/SF 
and c-met Co-expression o f HGF/SF and c-met has also been detected in pancreatic 
cancer, peripheral nerve sheath tumour and gliomal cells 22,63.149,234 addition, 
HGF/SF expression has been observed in both epithelial and stromal cells o f  breast 
cancer and gastro-intestinal tissues 202,317,318 y^ i-|-}^ ough HGF/SF is primarily thought to 
act in a paracrine fashion this may not be true for tumour cells. This conclusion is o f  
importance as in vitro generated HGF/SF autocrine loops promote both tumour invasion
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and metastasis in vivo 
Regulation o f  HGF/SF production
Fibroblast production o f HGF/SF in vitro  has been shown to be regulated by various 
agents, many being inflammatory cytokines. Interleukin l a  (IL-Ia), IL -ip , tumour 
necrosis factor-a (TNF-a), EGF, platelet-derived growth factor (PDGF), FGF and 
prostaglandins have been shown to increase HGF/SF expression (Figure 1.3) 90.120,171,292 
Oestrogen has been reported to increase HGF/SF gene transcription in the mouse ovary 
TGF-P and glucocorticoids block HGF/SF induction by IL-1 and other stimuli 
The 5'-flanking region o f the HGF/SF gene contain sequences homologous to 
responding elements o f  p53, retinoblastoma protein (Rb), IL-1, IL-6, glucocorticoids 
and TGF-P Injurin, a humoral factor that is produced in non-injured distant organs 
following hepatic or renal injury, induces HGF/SF mRNA in rat lungs Recently a 
second factor with HGF/SF converting effects has been characterised and termed 
hepatocyte growth factor activator (HGFA) which is activated exclusively by injured 
tissues
Co-culture experiments have indicated several possible in vivo  mechanisms o f HGF/SF 
regulation by epithelial cells, HGF/SF transcript levels in MRC 5 fibroblasts were 
initially reported to be decreased by co-culture with a human keratinocyte cell line 
through transcriptional regulation Similarly, Seslar et al observed inhibition o f  
HGF/SF expression in MRC 5 fibroblasts when co-cultured with several human breast
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Figure 1.3
Schematic illustration o f  activation, regulation and actions o f  HGF/SF on epithelial 
cells. HGF/SF is produced as inactive pro-HGF/SF that is proteolytically processed 
in extracellular stroma by urokinase plasminogen activator (uPA). Fibroblast 
production o f  HGF/SF is regulated by epithelial cells through SF-IF and TGF-p. 
Other factors such as oestrogen and inflammatoiy cytokines also promote HGF/SF 
production.
carcinoma cell lines In addition, the conditioned medium collected from these cells 
stimulated HGF/SF production. These findings indicate that epithelial cells produce 
factors that inhibit or stimulate fibroblast production o f  HGF/SF. Subsequent work 
identified the negative regulator as TGF-p The protein present in conditioned media 
responsible for inducing HGF/SF production has been identified as scatter factor- 
inducing factor (SF-IF), a 14 kDa heat stable protein
HGF/SF expression appears to be density dependent in vitro  Mesenchymal 
condensations, necessary for normal morphogenesis o f overlying epithelium, 
demonstrate high levels o f  HGF/SF expression in mouse embryos Similarly,
desmoplasia is often observed adjacent to invading cancer cells In this context, 
HGF/SF immunostaining in cancer tissues is concentrated at areas o f  tumour invasion
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The HGF/SF receptor: c-met
The receptor to HGF/SF, encoded by c~met, was first identified as an activated 
oncogene in the N-methyl-N'-nitro-N-nitrosoguanidine treated human osteosarcoma cell 
line (MNNG-HOS) by its ability to transform NIH 3T3 fibroblasts The identity o f  
the HGF/SF receptor was suggested by the observation that it stimulated the tyrosine 
phosphorylation o f a 145 kDa protein The molecular weight and ligand specificity 
suggested that it might represent a growth factor receptor kinase. The use o f  antibodies 
specific for different tyrosine kinases identified the 145 kDa phosphoprotein as the P- 
subunit o f the c~met proto-oncogene Cross linking experiments established the c-met
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protein as the HGF/SF receptor 22.206 p^^^bermore, kinase activation and cross-linking 
to the c-met protein was observed in a variety o f cells that responded to HGF/SF 
23,100.202,205 pj-ansfection o f MDCK cells with a hybrid cDNA encoding the ligand 
binding domain o f a nerve growth factor (NGF) receptor, trk, with membrane and 
cytoplasmic domains o f  c-met conferred NGF-responsiveness in motility, proliferation 
and morphogenic assays The pleiotropic effects o f HGF/SF therefore appear to be 
mediated by one receptor 4^i.32i mature form o f the receptor is a heterodimer 
consisting o f a 45-50 kDa extracellular a-subunit linked via disulphide bonds to a 140- 
145 kDa p-subunit that contains extracellular, transmembrane and intracellular catalytic 
domains (Figure 1.4) The c-met gene has been mapped to chromosome 7 at q21- 
31 and encodes a 1408 amino acid glycoprotein which lacks significant homology to 
any other growth factor receptor C-met has been found to belong to a family which 
includes proto-oncogenes Ron and c-sea ^^ 220,241
HGF/SF receptor expression and regulation
C-met is expressed by breast epithelial cells and a wide range o f other epithelial cells 
26,118,303 Yagjj^iar endothelium is also known to express c-met The receptor is 
primarily located at intercellular junctions in conjunction with cell adhesion molecules 
such as E-cadherin Ligand binding o f the c-met protein is associated with the 
activation o f its catalytic activity The major autophosphorylation site is Y1235 
which corresponds to the primary autophosphorylation site o f other tyrosine kinases 
C-/wc/-protein levels in hepatocyte cell cultures appear to be influenced by cell density.
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Schematic comparison showing several growth factor receptors containing intra­
cellular tyrosine kinase domains.
Confluent cells express low levels, whereas at low density higher expression is found 
21,183 mRNA levels are strongly upregulated by the cytokines IL-1 a , lL-6, TNF-
a , and TGF-p in human breast, ovarian and endometrial carcinoma cell lines 
Furthermore, steroidal hormones such as oestrogen, progesterone, and tamoxifen have 
similar effects on certain ovarian and endometrial cancer cell lines C-met mRNA 
levels undergo continuous turnover with half lives o f  less than 30 minutes, suggesting 
that c-met may behave as an immediate response gene An increased level o f  c-met 
mRNA has also been detected following cell stimulation with nanomolar concentrations 
o f HGF/SF This observation suggests that cell response to HGF/SF may be 
autoamplified by inducing its specific receptor.
Post receptor signal transduction
The pleiotropic responses induced by HGF/SF occur through the one receptor encoded 
by c-met 9^.188,309,320,321,349 molecular basis for these divergent responses is not fully 
understood. Protein engineering experiments indicate that mitogenic and motogenic 
responses diverge at the post receptor level Such diverse responses are therefore 
likely to result from the integration o f several transductional pathways activated by 
coupling o f  the HGF/SF receptor to cytoplasmic transducers. Interactions with other 
cytokines and ECM molecules may also modulate the type o f response.
Ligand binding to tyrosine kinase growth factor receptors results in dimérisation and 
autophosphorylation. However, c-met appears to form non-covalent clusters on cell
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membranes in vitro suggesting that multimersisation may be required for signal 
transduction The HGF/SF receptor, when autophosphorylated, binds to a number o f  
substrates containing Src homology 2 domains (SH2) such as phosphoinositide 3-kinase 
(PI 3-kinase), Ras-guanine nucleotide activating protein (Ras-GAP); phospholipase C- 
r (PLC-y) , ppôOsrc and the GRB-2-Sos complex (Figure 1.5) 8-“ .w.225.226 
cytoplasmic domain contains specific tyrosine phosphorylation sites (Y1234 and 
Y1235) that positively regulate the kinase activity o f  the receptor 159.204 
Phosphorylation o f Serine 985 has been shown to negatively regulate kinase activity 
Tyrosines 1347 and 1345 o f  the HGF/SF receptor form a docking site that mediate 
direct interactions with Pl-3 kinase, PLC-y, ppôOsrc and GRB-2-Sos Particular 
tyrosine residues in the intracellular domain o f the c-met protein have specific 
properties. Tyrosine 1356 appears to associate with GRB-2 protein and is essential for 
the transduction o f HGF/SF induced motility and morphogenesis in MDCK cells 
Tyrosines 1347 and 1354 are also associated with both HGF/SF induced motility and 
morphogenesis in MDCK cells
Phosphorylation o f  PLC-y has been detected following c-met activation This results 
in the hydrolysis o f  phosphatidylinositol-4,5-P2 (PIP2) to form diacyl glycerol (DAG) 
and inositol triphosphate (IP3). DAG and IP3 stimulate distinct downstream signalling 
pathways, protein kinase C (PKC) and calcium mobilisation. The activation o f PKC by 
HGF/SF-c-wer interaction can result in stimulation o f  MAP (mitogen activated protein) 
kinase pathways but can also result in negative regulation o f  c-met activity PLC-y 
activation is necessary for cell motility and is related to the mobilisation o f  several
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Figure 1.5
HGF/SF-c-we/ signal transduction pathways. HGF/SF binds to and induces tyrosine 
phosphorylation o f  the c-met receptor. This promotes binding o f  intracellular signalling 
proteins containing src homology (SH2) regions such as PLC-y, guanine nucleotide 
exchange factors and PI-3 kinase. Each SH2-containing protein may activate a differ­
ent subset o f signalling phosphopeptides thus eliciting different responses within the 
cell.
actin-modifying proteins such as gelsolin and profilin Ras, rho, ra f  and rac proteins 
are also involved in c~met signalling. Activation o f  c~met results in activation o f  Ras- 
GAP which in turn interacts with effector proteins including the serine/threonine kinase, 
ra f  Growth factors induce alterations in cell movement and cell shape by 
remodelling the actin cytoskeleton. Such alterations are mediated by the rho subfamily 
{rho, rac and cdc42) o f  small guanine nucleotide binding proteins. HGF/SF activates
rho and its associated proteins which in turn induce alterations in the actin framework
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Biological activities o f  HGF/SF and c-met
From its initial discovery, HGF/SF has been implicated in the processes that regulate 
tumour cell behaviour. HGF/SF has been shown to induce cell growth, motility and 
invasiveness that play a physiological role in development. However, these processes 
are similar to those promoting tumour invasion and metastasis,
HGF/SF regulates motility and growth o f cancer cells
HGF/SF stimulates motility and growth o f many tumour cell types although the degree 
o f  response may vary. Three types o f  response have been observed: increased 
proliferation and motility; decreased proliferation and motility; no effect on motility but 
varied effects on proliferation. The type o f  response observed is dependent on tumour 
cell type HGF/SF and c-met may be involved in cell cycle regulation. C-met
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expression has also been observed to be cell cycle dependent, the level o f  expression 
being highest at G2M and decreasing from S phase to GO/Gl HGF/SF stimulates 
DNA synthesis/proliferation in a wide range o f epithelial cells including mammary 
epithelial cells, hepatocytes, biliary epithelial cells, kératinocytes, melanocytes, 
melanoma cells, gastric, colonic and lung cancer cells, and vascular endothelial cells 
25,91,98,128,167,197,252,269,285,339 has been fouttd to bc ussociated with Bag-1, a protein
involved in mechanisms that prolong cell survival. The formation o f  Bag-l-c-/ner 
complexes increases rapidly following the induction o f apoptosis This suggests that 
HGF/SF-c-mar may be involved in both regulation o f cell growth and death.
HGF/SF and cancer invasive/metastatic behaviour
The metastatic cascade is composed o f  separate steps: loss o f  cell-cell adhesion; 
adhesion followed by invasion o f  basement membrane and ECM; intravasation, travel 
and survival in circulation; adhesion to endothelium followed by extravasation; 
fonnation o f  secondary foci supported by angiogenesis. HGF/SF has been implicated in 
several o f  these processes.
HGF/SF. cell-cell adhesion and motility
The dissociation/motility promoting properties o f  HGF/SF were described by Stoker et 
al on human mammary epithelial cells in vitro Increased motility and migration has 
been seen in several cancer cell types including breast 42,123,125,274,280
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Following stimulation o f  tumour cell colonies with HGF/SF, membrane ruffling is seen 
preceding dissociation Intercellular cell-cell contacts are mediated by cell
surface adhesion molecules. There is evidence for HGF/SF inhibiting cell adhesion 
systems. HGF/SF treated cells fail to form stable cell-cell adhesion junctions through 
increased stability o f  newly synthesised soluble E-cadherin and altered phosphorylation 
o f  E-cadherin within the cell Cadherin function is modulated by intracellular 
proteins named catenins. HGF/SF has been shown to enhance the tyrosine 
phosphorylation status o f  p-catenin which in turn down regulates cadherin mediated cell 
adhesion 9^5,270,295 yj^us HGF/SF promotes dismantling o f  cell-cell adhesion complexes 
and inhibits the formation o f  adherens junctions The HGF/SF receptor, c-met, is 
located at intercellular junctions together with cell adhesion molecules such as E- 
cadherin However, whether this localisation pattern facilitates physical interactions 
between these molecules is unknown.
HGF/SF. cell-matrix adhesion, matrix degradation and invasion
The basement membrane and ECM form the first barrier that tumour cells encounter 
through the metastatic process. Tumour cells adhere to ECM via the integrin family o f  
cell-adhesion molecules. Integrins in turn interact with intracellular cytoskeletal 
elements. Following integrin binding, focal adhesions are formed consisting o f  
integrins, p i25 FAK (focal adhesion kinase) and paxilin. During malignant 
transformation, changes in integrin expression have been observed and may contribute 
to anchorage-independent growth and invasion HGF/SF increases adhesion o f c-
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met positive lymphoma cells to fibronectin and promotes migration and invasion 
HGF/SF has been shown to increase integrin expression in both breast and liver cancer 
cells thus increasing their matrix adhesive properties fjQp/gp also affects the
initial recruitment o f integrins, cytoskeletal proteins, p i25 FAK and paxilin into focal 
adhesion complexes via c-met
Following the adhesion to ECM, tumour cells must invade this barrier. HGF/SF induces 
the invasion o f a number o f epithelial cells through collagen matrices and basement 
membranes 19,15,115,169,244,247,274,283,320 rppG formation o f  HGF/SF-c-mer autocrine loops
have been shown to promote tumour cell invasiveness in NIH 3T3, SK-LMS-1 and 
C127 breast cancer cells Invasion o f  ECM components require the action o f  
activated proteolytic enzymes. The tpr-met hybrid is known to activate the urokinase 
plasminogen activator (uPA) gene The production o f uPA and collagenase are 
increased by HGF/SF ^^^,247 y^cse proteases may be involved both in ECM degradation 
and activation o f  HGF/SF. HGF/SF also stimulates cancer cell production o f  matrix 
metalloproteinases, collagenase-1 and stromelysin-1 .
To gain access to the circulation, tumour cells must bind to endothelial cells. HGF/SF 
has been shown to increase the adhesion o f  tumour cells to endothelium. HGF/SF 
increases expression o f  integrins a-2  which promotes tumour cell adhesion to matrix 
and to endothelial cell substrates HGF/SF also increases the expression o f CD44 on 
endothelial cells, a molecule which may be involved in tumour-endothelial interactions 
and establishment o f  métastasés Melanoma cells with high c-met and HGF/SF
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activity demonstrate increased liver colonisation 254
HGF/SF and morphogenesis
The ruffling o f  free edges on the apical surface o f  cells is one o f  the earliest 
morphological events to occur following HGF/SF stimulation Montesano et al 
observed MDCK cells forming organised tubular structures when grown in collagen 
gels in the presence o f  HGF/SF obtained from fibroblast conditioned medium or when 
grown with fibroblasts Tsarfaty et a l demonstrated that HGF/SF induced human 
breast and colonic carcinoma cells to form lumen like structures in vitro Both non- 
parenchymal liver epithelial cells and prostate epithelial cells in collagen matrices 
demonstrate branching morphogenesis when stimulated by HGF/SF Similar
morphoregulatory properties in epithelial cells have not been observed to the same 
degree by other growth factors such as EGF, basic FGF, TGF-j3, insulin-like growth 
factor (IGF) or PDGF HGF/SF has also been reported to stimulate the formation 
o f  tubular structures by vascular endothelial cells in vitro and angiogenesis in vivo 
25,94,190,245 vivo, HGF/SF has been shown to generate axial structures in chick 
embryos HGF/SF-c-mer is an important mediator o f limb and hepatic development 
Mice lacking HGF/SF demonstrate placental defects and embryonic lethality
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HGF/SF and angiogenesis
Angiogenesis is a prime requirement for tumour growth and metastasis. Angiogenesis 
requires a number o f features such as proliferation and migration o f endothelial cells 
and appropriate regulation o f endothelial cell-cell and cell-matrix adhesion. HGF/SF 
stimulates endothelial cell proliferation in vitro In vivo studies also demonstrate 
HGF/SF to be a powerful inducer o f angiogenesis in rodents ^^ >94,243 ypg angiogenic 
promoting properties o f HGF/SF are amplified by tissue plasminogen activator (tPA) 
and vascular endothelial growth factor (VEGF) HGF/SF induced angiogenesis may 
occur by autocrine or paracrine mechanisms as both HGF/SF and c-met are expressed in 
endothelial and vascular smooth muscle cells 9^9,2oo cells produce active
HGF/SF which stimulates angiogenesis in a paracrine fashion 4^7449 sijnilarly, breast 
cancer cells transfected with HGF/SF are able to stimulate angiogenesis as part o f a 
mechanism o f increased tumorigenicity^"^ .^
HGF/SF in tumour-stroma interaction
Interactions between epithelium and mesenchyme mediate important aspects o f normal 
growth, morphogenesis and neoplasia. The growth, differentiation and morphogenesis 
o f developing epithelia are regulated by the neighbouring mesenchyme o f various 
organs During development, HGF/SF is expressed predominantly in mesenchymal 
cells whereas c-met expressed in cells o f  epithelial origin HGF/SF induces and 
organises branching tubulogenesis o f  kidney, lung and mammary gland
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187,208,213,262,276,334 yjjus, duiing organogcncsis HGF/SF plays an important role as a 
mesenchymal derived mediator o f organised cell growth, movement, morphogenesis 
and ECM remodelling.
Stromal influence on epithelial neoplasia and malignant progression o f carcinoma cells 
has been reported in a number o f  cancers including breast cancer ^^>260,312 growth 
o f  certain carcinoma cells in vivo  is accelerated by fibroblasts. Furthermore, in vitro  and 
in vivo  invasiveness o f  several carcinoma cells are induced by the co-existence o f  
stromal fibroblasts 29,96,168,221 humour cell invasion and métastasés may therefore be 
driven by a number o f stromal-derived factors. Although the molecular mechanisms 
involved in tumour-stroma interactions are not fully understood, HGF/SF may be 
involved.
HGF/SF has been identified as a fibroblast-derived invasion factor in vitro. Most 
carcinoma cells in vitro do not invade ECM e.g. collagen gels *2,168,264 o f  oral
squamous cell carcinoma cells has been shown to be induced by incorporation o f  
normal fibroblasts or conditioned medium into collagen gels The factor responsible 
for inducing this invasiveness was identified as HGF/SF Subsequently Weidner et a l 
demonstrated HGF/SF induced invasion and migration o f a wide variety o f  tumour cells
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HGF/SF production may be stimulated by tumour-derived inducers. Human breast 
cancer cells are able to regulate fibroblast production o f  HGF/SF by SF-IF and TGF-p
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246,268 HGF/SF inducers have been shown to be produced by tumour
including: IL-1 a , IL-ip, basic FGF, PDGF and prostaglandin ^^9,173,195 cytokines
and growth factors transcriptionally activate gene expression o f HGF/SF 9o ,n  1,174,195,238
Tumour progression may involve the presence o f a HGF/SF inducer loop. Tumour cells 
appear to produce factors that induce fibroblast production o f HGF/SF and fibroblasts 
then secrete HGF/SF which stimulates invasive growth. Co-culture experiments have 
demonstrated the existence o f  these interactions in vitro. O f importance, in these 
experiments invasion was inhibited by both antibodies against HGF/SF and inhibitors o f  
HGF/SF inducers ^^ »^^ 96,i7o,i95 -phc stromal matrix may act as a reservoir for HGF/SF. 
HGF/SF binds to several matrix proteins including thrombospondin-1 (TSP-1), 
fibronectin, laminin, collagen type 1, heparan sulphate and basement membrane 
131,148,161 bound HGF/SF is still able to exert biological functions
HGF/SF and tumour metastasis
HGF/SF-c-me/ autocrine stimulation has been observed to promote tumour invasion and 
metastasis in vivo (Figure 1.6). NIH 3T3 cells transfected with c-met exhibit a high 
frequency o f lung métastasés compared with control cells when implanted in nude mice 
Furthermore, U.GF/SV-c-met signalling facilitated NIH 3T3 cells to colonise organs 
such as lung, heart, diaphragm and retroperitoneum Similar findings were observed 
in C127 breast cancer and SK-LMS-1 leiomyosarcoma cells In vitro treatment o f  the 
c-met expressing EMT6 mouse mammary tumour cell line with HGF/SF has also been
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Figure 1.6
Illustration o f  the role o f  HGF/SF in tumorigenicity and invasion/metastasis. Autocrine 
HG¥/SF-c-met loops in C127 and EMT6 breast cancer cell lines have been shown to 
induce métastasés in distant organs when implanted into nude mice. It is thought that 
HGF/SF-c-mel loop promotes tumour growth, invasion, motility and angiogenesis that 
are essential steps o f  disease progression.
shown to enhance in vivo metastatic ability These studies demonstrate that autocrine 
expression o f HGF/SF and c-met strongly promote métastasés. The mechanisms that 
contribute to this observation may include increased cell growth and angiogenesis as 
discussed above. In addition, HGF/SF stimulates cell dissociation and motility. Finally 
HGF/SF stimulates the production o f  proteases that may participate in tumour cell- 
mediated degradation o f  basement membrane and ECM.
HGF/SF, c-met and their relationship with tumorigenesis
HGF/SF and c-met have been implicated as mediators o f  tumour metastatic progression 
in vivo because o f  their profound stimulatory effects on tumour cell functions that are 
central to the process o f  metastasis. The HGF/SF- c-met system has been shown to 
induce tumour formation either through the oncogene tpr-met or by autocrine signalling 
C-met was first identified as a proto-oncogene through its ability to transform NIH 
3T3 cells in the rearranged oncogene tpr-met Expression o f  this oncogene in 
transgenic mice has been associated with the development o f mammary hyperplasia and 
tumours
Autocrine expression o f HGF/SF and c-met has been shown to induce transformation 
and tumorigenicity in vitro. NIH 3T3 cells naturally produce HGF/SF but little or no c- 
met protein. Transformation and tumorigenicity is induced by genetic transfer o f  c-met 
In addition, spontaneously transformed NIH 3T3 cells often overexpress c-met 
protein In this murine system, transfection o f  human c-met does not result in
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transformation unless human HGF/SF is co-transfected This observation indicates 
that overexpression o f unaltered c-met does not induce transformation o f cells that do 
not produce or have access to HGF/SF. Similar observations have been reported in 
C l27 breast cancer cells, SK-LMS-1 leiomyosarcoma cells and NBT-II bladder 
carcinoma cells
The biological processes underlying HGF/SF-c-mer induced tumorigenicity are not fully 
understood, However, three mechanisms may play a role in this process. Firstly, 
HGF/SF-c-met is mitogenic to a number o f cells and uncontrolled autocrine induced cell 
growth contributes to tumour formation. In support o f this hypothesis tumour formation 
in HGF/SF-c-mc/ stimulated NIH 3T3, C l27 and SK-LMS-1 cells involves increased 
cell growth Secondly, HGF/SF-c-mc/ has been shown to induce angiogenesis and 
this may contribute to tumour formation. Finally, HGF/SF induces the expression o f  
both uPA and its receptor which are necessary for HGF/SF activation
HGF/SF and c-met in human cancers
The expression o f HGF/SF and its receptor has been investigated in numerous human 
cancers. The following changes have been observed in tumour: overexpression, aberrant 
expression, receptor mutation and possible over-autophosphorylation The c-met 
proto-oncogene is overexpressed in several types o f human cancer. Initial studies by Di 
Renzo et a l and Prat et a l reported overexpression o f c-met in human carcinomas o f the 
colon, stomach, pancreas, small bowel, thyroid, ovary, kidney and brain
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Gastro-intestinal cancers
Both c-met and HGF/SF overexpression have been reported in gastrointestinal cancers. 
High levels o f tumour HGF/SF has been associated with reduced survival in patients 
with squamous cell carcinomas o f  the oesophagus In gastric cancers frequent 
amplification o f the c-met gene has been observed Overexpression o f  c-met mRNA  
in human gastric cancer appears to be associated with local tumour invasion and lymph 
node metastasis Circulating levels o f  HGF/SF are increased in patients with primary 
and recurrent gastric cancers. Increased levels have been found to correlate with 
histological tumour and venous invasion C-met mRNA levels are increased in both
colonic adenomas and colorectal cancers In a series o f 123 colon cancers, Flavia et
al observed that c-met was overexpressed in 50% o f primary tumours and in 70% o f  
métastasés, suggesting a link between overexpression and disease progression 
Tumour concentration o f  HGF/SF in colon cancers is increased when compared to 
normal tissue Furthermore, serum concentration o f  HGF/SF have been shown to 
correlate with Dukes classification, lymph node involvement and liver métastasés 
Co-expression o f HGF/SF and c-met have been observed in human pancreatic cancers 
and levels o f mRNA were significantly increased in tumour when compared to normal 
tissue In hepatocellular carcinomas c-met expression was found to correlate with 
reduced tumour differentiation
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Urinary tract tumours
In human prostate cancers c-met expression is increased when compared to normal 
tissue. Increased c-met expression also correlated to higher tumour grade Co­
expression o f both c-met and HGF/SF is reported in human bladder cancers In
addition, elevated levels o f  HGF/SF are associated with high grade tumours in human 
bladder cancer
Thvroid cancer
C-met overexpression has been detected in thyroid cancers. The significance o f  
overexpression is the subject o f controversy. One study demonstrated a relationship 
between overexpression and poor prognostic histology However, Belfiore et a l 
demonstrated a relationship between low levels o f expression and distant métastasés .^ 
Another study demonstrated c-met expression in the majority o f papillary carcinomas 
with a relationship to poorly differentiated tumours
Lung cancer
Levels o f immunoreactive HGF/SF are significantly higher in non-small cell 
carcinomas when compared to other tumour types The level o f tumour HGF/SF was 
found to be a good indicator o f patient survival. Other studies have shown a relationship 
between c-met expression and prognosis in lung cancer Although HGF/SF levels are
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elevated in the sera o f lung cancer patients, no relationship between serum levels and 
prognosis have been reported HGF/SF is present in a large proportion o f  malignant 
pleural effusions due to secondary spread from a number o f tumour types
Brain and tumours o f nervous system
Gliomas have been found to express both HGF/SF and c-met. In addition gliomas have 
been observed to secrete active HGF/SF. In peripheral nerve sheath tumours, expression 
o f HGF/SF and c-met is negative in benign and positive in malignant tumours 
HGF/SF and c-met expression has also been found to correlate with grade o f  
malignancy
Other tumours
C-met overexpression and co-expression o f  both HGF/SF and c-met has been observed 
in several osteosarcoma cell lines Skin cancers and haemopoetic malignancies also 
demonstrate aberrant HGF/SF and c-met expression
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Proposal for thesis
HGF/SF appears to function as a paracrine regulator for the growth, dissociation, 
motility and invasiveness o f  epithelial cells and for angiogenesis. In addition HGF/SF- 
c-met may be an important stromal-epithelial regulator o f  epithelial morphogenesis in 
development. However, aberrant HGF/SF-c-mer signalling has been shown to induce 
transformation and promote tumour invasion and metastasis both in vitro and in vivo 
(Figure 1.7) "s,
HGF/SF was first identified as a soluble factor that dissociates human breast epithelial 
cells in culture HGF/SF-c-mer may also play a role in morphogenesis o f  breast 
ducts. Human breast epithelial cells form lumen-like structures in the presence o f  
HGF/SF in vitro  HGF/SF-c-me/ is therefore a candidate gene participating in 
stromal-epithelial regulation o f  breast duct development. This is supported by evidence 
that breast epithelial cells in vitro can regulate fibroblast production o f HGF/SF 
Furthermore both HGF/SF and c-met expression are induced by oestrogen Loss 
o f  regulation o f  morphogenic pathways may result in uncontrolled cell dissociation, 
motility, invasiveness and ultimately metastasis. There is evidence that aberrant 
HGF/SF-c-we? expression may occur in human breast cancer. Levels o f HGF/SF are 
increased in breast cancer homogenates Furthermore, LOH o f  c-met in human breast 
cancer is associated with both reduced disease-free and overall survival The 
expression status o f  c-met in breast is controversial. Initial studies failed to detect c-met 
expression in breast-tissue, although it was known that breast epithelial cells responded
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Figure 1.7
Hypothetical illustration o f HGF/SF-c-/wer interaction in normal and malignant cells. In 
normal cells, HGF/SF promotes co-ordinated cell growth, dissociation, invasion and 
motility which manifest as morphogenesis. In malignant cells these component actions are 
excessive and exhibit loss o f  co-ordination resulting in metastasis. Functional E-cadherin is 
an important determinant in HGF/SF induced morphogenesis and metastasis.
to HGF/SF However, Tsarfaty et a l detected c-met expression in breast cancers 
and in adjacent tumour-free breast tissue The aim o f  this thesis is to further 
investigate the role o f HGF/SF and c-met in human breast cancer.
Aims o f studv
1. To investigate the frequency and significance o f LOH o f c-met in patients with
breast cancer.
2. To investigate HGF/SF and c-met expression in patients with breast cancer.
3. To correlate HGF/SF expression with tumour proliferation and angiogenesis in
patients with breast cancer.
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Chapter 2: Investigation on frequency o f loss of heterozygosity o f the c-met 
proto-oncogene in human breast cancer
Introduction
In 1992 Bieche et al detected a high frequency o f  allelic loss (40.5%) using the pmet H 
polymorphic probe among 121 informative (heterozygous) patients at the c-met locus 
(7q31) with primary breast cancer In addition, these patients demonstrated 
significantly shorter metastasis-free and overall survival. This study provided the first in 
vivo  evidence o f  a link between abnormal HGF/SF-c-we^ function and disease 
progression in breast cancer. Bieche et al concluded that an important tumour or 
metastasis suppressor gene was present at the c-met locus. This observation had not 
been reported before and required further investigation.
Genetic events resulting in the development o f  cancers are thought to involve activation 
o f cellular oncogenes and loss o f  function o f  tumour suppressor genes. These events are 
thought to occur in a multistep fashion. Loss o f heterozygosity (LOH) analysis o f  
polymorphic DNA markers point to chromosomes and subregions o f chromosome arms 
likely to harbour tumour suppressor genes However only in a few  instances have 
actual genes, such as Rb or p53, relevant to allelic loss been identified. Breast cancers 
appear unusual among human tumours for the great degree o f  genetic heterogeneity 
displayed. LOH in carcinoma o f  the breast affects at least 13 chromosome arms. 
According to Knudson’s Hypothesis this would suggest that more than 20 genetic loci
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may undergo mutation followed by allelic loss during the initiation and progression o f 
breast cancer Alternatively, many o f these LOH could be irrelevant and may result 
from chromosome disintegration. This is in contrast to colorectal cancer where allelic 
loss is mainly restricted to six chromosomes
LOH studies from many groups have shown that the following regions o f  the genome 
undergo allelic loss at the approximate frequencies indicated (only frequencies o f 30% 
or greater listed): Chromosome Ip (40%), 3p (40%), 6q (35%), 8p21~22 (55%), 9p 
(65%, attributed to the CDK inhibitor p l6), l lq  (40%), 13ql2-13 (35%, potentially 
related to BRCA-2), 16q(50%), 17p (55%, attributed in part to p53), 17q (40%), 18q 
(35%), 22q (40%) 27.28.30.32,38,51,154,191,336,342 ^  recent genome-wide search for LOH in 
56 regions o f  the genome in human primary breast cancer confirmed a variable pattern 
o f allelic loss in the majority o f cases with the most frequently deleted regions being 8p, 
l lq ,  16q and 17p The possible involvement o f specific tumour suppressor genes in 
the later stages human cancer is not clear. Putative metastasis-related genes have been 
identified using cell lines and rodent models. These studies have linked metastatic 
phenotypes to genes such as NME-1 (17q), CDHl (16q), T S G lO l(llp ) and KISSl (Iq). 
In breast cancer relapse samples candidate metastasis related genes targeted by LOH 
have been identified on 3p21.3 and 16q22.2-23.2
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Materials and methods
The use o f  restriction fragment length polymorphism (RFLP) analysis o f DNA is a well 
established method o f  detecting tumour suppressor genes in human cancer. The pmet H 
probe recognises RFLP o f  4.0 and 7.5 kb on Southern blot electrophoresis enabling 
heterozygous (informative) cases to be identified from blood analysis. Tumour DNA  
from informative cases are then analysed for LOH.
Preparation o f probe
Identification o f  c-met locus in both blood and tumour DNA was performed using the 
pmet H probe obtained from American Type Culture Collection, Maryland, USA  
(ATCC). The pmet H probe is a 1.6kb fragment prepared from the plasmid pBR322. 
This probe recognises the 7.5 and 4.0 kb Taql restriction fragments. E.coli D H l 
containing the plasmid pBR322 with the 1.6kb metH insert was rehydrated and grown 
overnight in a shaking incubator at 37°C in 10ml o f  Luria Bertani medium (lOgms 
bacto-tryptone, 5gms bacto-yeast extract, lOgms sodium chloride [NaCl] , 950mls 
distilled water) containing ampicillin at a final concentration o f O.lpg/ml. The culture 
was spun down at 300 rpm for 15 minutes. The cell pellet was retrieved, resuspended in 
350pl o f  cold STET buffer (50mM Tris pH 8.0, 50mM EDTA, 8% sucrose, 5% Triton 
X-lOO) and 25pl o f  fresh cold lysosyme (lOmg/ml) added. This was left on ice for 5 
minutes, placed in boiling water for 60 seconds and then centrifuged at 13,000 rpm for 
15 minutes. The supernatant was retrieved and 1/10 volume o f  3M sodium acetate and
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phenol equilibrated with 0.5M Tris (pH 8,0) added. The aqueous phase was then 
retrieved and plasmid DNA precipitated with 0.6 volume o f propan-2-ol for 30 minutes 
at “20°C. The precipitate was centrifuged at 13,000 rpm for 5 minutes. The plasmid 
D NA  pellet was retrieved, washed in 95% ethanol, vacuum dried and dissolved in lOOpl 
o f water. Plasmid DNA was digested with EcoRI and Sail restriction enzymes (50pl 
plasmid DNA, 6.5|ul KGB buffer [2x KGB: 200mM potassium glutamate, 50mM Tris- 
acetate, 20mM magnesium acetate, 100|ug/ml bovine serum albumin, ImM  
mercaptoethanol], 2.5pl EcoRI, 2.5pl Sail, 3p,l spermidine) overnight at 37°C. 4pl o f  
loading mix (8gms sucrose, 2.4mls 50x electrophoresis buffer, 50mgs bromophenol 
blue) was added to the digest. A  1.0% low melting point agarose gel was prepared using 
electrophoresis buffer (50x: 2420gms Tris, 571mls glacial acetic acid, IL 0.5M EDTA 
pH8, made up to lOL) and stained with ethidium bromide. The digests were 
electrophoresed next to a I kb ladder at 40mAmp for three hours. Two bands o f  just 
greater than 4 and Ikb were identified corresponding to restriction digests analysed on 
agarose gels giving the EcoRI/Sall 4.2 and 1.25 kb fragments (Figure 2,1). The 1.2kb 
band was cut out, mixed with three times its weight o f  water and placed in a water bath 
for 10 minutes at lOO^C. This was divided into aliquots o f  25pl and frozen at -20^C 
until required.
Collection o f  paired samples o f  blood and tumour from primary breast cancer patients
Paired samples o f  tumour and blood from 111 patients treated with primary breast 
carcinoma at the Western Infirmary, Glasgow were studied. None o f these patients had
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< C = I  4.2 kb
1.25kb
Figure 2.1
DNA electrophoresis o f  restriction digests with Sail and EcoRI o f  plasmid DNA. 
Lane 1: Ikb ladder, lane 2; plasmid DNA digests.
4.2 and 1.25 kb fragments were detected.
received preoperative cytotoxic, endocrine or radiotherapy. Tumour and blood samples 
were collected and immediately frozen at -70^C until needed. These samples were 
collected from a larger tumour bank for which patient consent and ethical committee 
approval had been obtained. The presence o f tumour in samples investigated were 
confirmed by routine histopathology. Clinico-pathological data including age, tumour 
type, tumour size, histological grade, oestrogen receptor and axillary nodal status were 
retrieved.
De-oxvribonucleic acid (DNA) extraction from blood and tumour 
Extraction o f blood DNA
Two volumes o f  lysis buffer (lOmM Tris pH 8.0, O.IM EDTA pH 8.0, 20pg/ml 
pancreatic RNase, 0.5% sodium dodecyl sulphate [SDS]) was mixed in 5mis blood and 
then centrifuged at 5^C for 15 minutes at 2500 rpm. The supernatant was then discarded 
and 2mls nucleic acid lysis buffer (40mls 5M NaCl, 5mls IM Tris, 2mls 0.5M EDTA  
pH 8.2, 500mls distilled H2O), 175pf 10% SDS and lOOpl proteinase K added. The 
mixture was incubated overnight at 37®C in a water bath. The following morning, 700pl 
o f  5M NaCl was added and the mixture centrifuged at 5^C for 15 minutes at 2500 rpm. 
The supernatant was decanted and 700pl o f  phenol/chloroform (Igm  hydroxyquinolone, 
4gms Tris, 1.5L water saturated phenol made up to 1:1 mixture with chloroform) added. 
This was gently mixed and then centrifuged at 1200 rpm for 10 minutes at room 
temperature. The supernatant was decanted and an equal volume o f  ethanol added. The 
precipitated DNA was spooled onto glass rods, air dried and dissolved in 0.5ml o f Tris-
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EDTA (TE) buffer. Samples were stored at -20 C until needed.
Extraction o f tumour DNA
Breast tumour samples were thawed over ice and mechanically disaggregated in 200pl 
o f  10% SDS and 2mls o f  nucleic acid lysis solution. This was placed in a universal 
container where 200|l i 1 o f  10% SDS, 2mis o f  nucleic acid lysis solution and 200pl o f  
proteinase K added. The mixture was incubated overnight at 37^C. Afterwards, 1.4mls 
o f  6M NaCl was added and centrifuged at 2500 rpm for 15 minutes at 15^C. The 
supernatant was retrieved and 700pl o f phenol/chloroform added, mixed and 
centrifuged at 1000 rpm for 10 minutes at room temperature. The DNA was precipitated 
by adding 3 volumes o f  ethanol. The DNA was spooled onto glass rods, air dried for 10 
minutes, dissolved in 0.5ml TE buffer and stored at -20^C until needed.
DNA quantitation
DNA was quantified by spectrophotometry. lOpl o f DNA solution was diluted in 990 pi 
o f TE buffer and mixed thoroughly. The optical density (OD) was then measured at 
260nm. DNA concentration was then calculated as the product o f OD260 x dilution 
factor (100) x 50.
49
Genomic DNA digestion
Blood DNA was first analysed to determine informative (heterozygous) cases for the c- 
met gene. Tumour samples from these cases were then analysed for LOH. The protocols 
for genomic digestion, electrophoresis, preparation o f filters, hybridisation and 
autoradiography were the same for both instances. Restriction digests o f  40pl total 
volume were prepared as follows; 5pg sample DNA, 4pl buffer (react 2 for Taq 1, 
Gibco BRL, Paisley, Scotland), 3 pi Taq 1, 2pl spermidine, variable volume o f 
deionised water depending on DNA concentration. The digests were incubated in a 
waterbath set at 65^C overnight.
Southern blot electrophoresis 
Preparation o f gels
DNA digests were separated by electrophoresis in 0.7% agarose gels. This was prepared 
by dissolving 2.8mgs o f agarose in 400mls o f electrophoretic buffer. This was boiled in 
a microwave oven for 5 minutes and stained with 12pl o f  ethidium bromide. A 22 lane 
plate was prepared and gel poured in when below 60^C. When set the gel was 
submerged in a sufficient volume o f  electrophoretic buffer. The DNA digests were 
stained with 4pl o f bromophenol blue and 35pi o f DNA digest loaded into the wells. 
Electrophoresis was commenced at 240mA for three hours. The gel was retrieved and 
treated with 0.25M hydrochloric acid for 15 minutes followed by 30 minutes o f  
dénaturation solution (1.5M NaCl, 0.5N sodium hydroxide) and a further 30 minutes
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with neutralisation solution (IM  Tris pH 7 .4 ,1.5M NaCl).
Southern blot transfer
Separated DNA fragments were transferred to a Hybond membrane according to the 
method described by Southern (Figure 2.2) This was left at room temperature for 2 
days. The membrane was retrieved and DNA fixed by baking at 80^C for 5 hours.
Membrane treatment 
Prehvbridisation
Membranes were rolled into a Hybaid bottle to which 7mls o f  hybridisation solution (6x 
saline-sodium citrate [SSC], 0.5% SDS, 5x Denhardfs solution) and 70pl o f salmon 
sperm DNA (denatured at lOO^C for 10 minutes) was added. The bottles were incubated 
in a Hybaid oven at 65°C overnight.
DNA radiolabelling
The pmet H probe was radiolabelled using a random primer labeling kit (Roche 
Diagnostics Ltd. [Boerhinger Mannheim] East Sussex, UK ). 25pl o f  the pmet H probe 
was boiled for 10 minutes and then incubated for 5 minutes at 37^C. To this was added 
6pl o f  deoxyadenosine triphosphate, deoxyguanosine triphosphate and thymidine 
triphosphate mixture, 4pl reaction mixture, 1.5pl Klenow enzyme and 5pi o f
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Weight (-500g) 
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Whatman 3MM paper
Spacers 
2 sheets of Whatman 3MM
Figure 2.2
Diagram of apparatus used for Southern blot of DNA onto Hybond membrane.
radiolabelled deoxycytidine triphosphate. The mixture was incubated at 37°C for 
two hours and labelled probe separated with a Sephadex G50 column washed down 
with Ix SSC/0.1% SDS. Approximately 0.5ml o f the peak radioactive solution was 
collected for probing.
Hybridisation o f filters.
The labelled probe was denatured by boiling for 10 minutes and mixed into the 
hybridisation solution. The membrane was hybridised at 65^C in a Hybaid oven 
overnight.
Washing o f membrane
Excess radioactive probe was washed from the hybridised membrane using 
2xSSC/0.1% SDS at 65^C in Hybaid oven for 30 minutes. This was repeated again in a 
water bath o f 2x SSC/0.1% SDS until the radioactive background was less than 10 
counts per second. The filter was blotted dry between sheets o f 3mm filter paper and 
then protected with a polythene sheet.
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Autoradiography
The membrane was placed in a light-proof cassette containing intensifying screens with 
Kodak Diagnostic X-OMAT AR5 fast film. The cassette was left overnight at -20®C and 
the fihn developed using an AGFA X-ray film processor (Curix 60 process). If the 
hybridisation signals were not strong enough the filter was exposed for a longer time. If 
the background was intense the membrane was washed and then re-exposed.
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Results
The pmet H probe
EcoRJ/Sall digests o f pBR322 plasmid with 1.6kb c-met insert produced the expected 
fragments o f  4.2 and 1.25 kb on agarose electrophoresis (Figure 2.1).
Patient population
111 patients with primary breast cancer were investigated for LOH o f  c-met in this 
study. The clinico-pathological variables o f  this group are summarised (Table 2.1).
Blood and tumour DNA analysis
The pmet H probe detected Taq 1 RFLP o f  7.5 and 4.0 kb (Figure 2.3). Visual 
inspection o f  ethidium bromide-stained gels and hybridisation signal intensity were 
used to compare the amount o f  DNA loaded in the different lanes. The intensity o f  
hybridisation to each restriction fragment was visually assessed. Samples with low  
levels o f DNA loading were re-evaluated. Analysis o f blood DNA demonstrated that 
52/111 patients (47%) were heterozygous for the Taq 1 RFLP o f 7,5 and 4.0 kb. 36/111 
cases (32%) were homozygous for the 7.5kb allele and 23/111 cases (21%) 
homozygous for the 4.0kb allele (Figure 2.3). In this study, o f  the 52 heterozygous
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Table 2.1
Clinico-pathological variables o f  breast cancer patients.
Clinico-pathological variable Number of Patients
Age Median 60 yrs (range 27-89 yrs)
Tumour size Median 25 mm (range 7-90mm)
<3 0mm 85
> 30mm 26
Tumour grade
1 16
2 65
3 30
Lymph node status*
Negative 55
Positive 55
Oestrogen receptor status**
Negative 40
Positive 60
Histological Type
Ductal 107
Lobular 4
* Lymph node status not known in one patient
** Oestrogen receptor status not known in 11 patients
7.5 kb
4.0 kb
2 3 4 5 6 7 8  9
Figure 2.3
Autoradiographs o f blood DNA demonstrating RFLP o f 7.5 and 4.0 kb. Lanes 1, 2, 7 and 
9 are homozygous for either 7.5 or 4.0 kb allele and are therefore non-informative. Lanes 
4 and 6 are heterozygous. Lanes 3, 5 and 8 are blank.
cases, total LOH was detected in only 2 tumour samples, a frequency o f 4% (Figure
2.4). Reduced signal intensity for the 7.5kb allele was observed in a further 5 cases. In 
this study therefore partial/total LOH was observed in 7/52 cases, a frequency o f  13%.
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7.5 kb
• • • 4.0 kb
8
Figure 2.4
Autoradiographs o f  breast cancer DNA demonstrating RF'LP o f  7.5 and 4.0 kb in patients 
found to be heterozygous for c-met following blood DNA analysis. LOH was detected in 
only two patients (lanes 1 and 6).
Discussion
Functional inactivation o f a tumour suppressor gene often involves deletion o f the 
normal allele to unmask the mutated allele. Chromosomal regions with frequent 
deletions are thought to harbour putative tumour suppressors Frequent LOH at a 
given chromosomal region has been interpreted as evidence that the affected region may 
contain a tumour-suppressor gene that is inactivated during the malignant process 
Chromosome arms demonstrating LOH o f  greater than 20% are thought to be o f  
potential interest in breast cancer In a review o f published allelotype data from over 
30 studies comprising more than 1000 breast tumour specimens, Devilee et a l identified 
11 chromosome arms showing LOH in greater than 25% o f investigated tumours and 2 
(16q and 17p) with LOH greater than 50%
Cytogenetic studies have revealed frequent chromosome 7 abnormalities in several 
tumour types including breast, gastric and prostate cancers 2^,287,315,330 breast cancers 
several karyotypes with numerical alterations (polysomy or monosomy 7 and 7p) and 
structural abnormalities on both arms o f chromosome 7 have been reported 
Furthermore, in vitro studies have also suggested the presence o f a tumour suppressor 
gene on chromosome 7. Microcell transfer o f human chromosome 7 into a murine 
squamous carcinoma cells has been shown to inhibit tumorigenicity Similarly, 
insertion o f intact human chromosome 7 into an immortalised human fibroblast cell line 
with 7q31-32 LOH suppressed the immortality of the cells and restored the ability for 
senescence However, cytogenetic methods detect only gross chromosomal changes.
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LOH analysis with either RFLP/microsatellite markers is a sensitive molecular method 
to screen for changes involving allele loss and by presumption, markers o f  tumour 
suppressor gene loss in tumours. Several investigators have suggested the presence o f  
an important tumour suppressor gene on 7q31.1 in a variety o f  human primary cancers 
(Table 2.2). Some o f these studies have also shown that LOH at 7q31.1 correlated with 
poor prognosis suggesting a role in tumour progression. LOH at 7q31.1 has been linked 
to tumour aggressiveness and poor prognosis in several human cancers including 
gastric, prostate, thyroid, ovarian and breast cancer suggesting a possible role in the 
development or progression o f  these malignancies 145,288,347
Microsatellite marker studies have attempted to locate the precise position o f  the 
smallest common deleted region o f 7q31.1 in a variety o f cancers which may identify 
the putative tumour suppressor gene (Figure 2.5), Zenklusen et a l have used several 
polymorphic microsatellite markers in an attempt to determine the location o f the 
putative tumour suppressor gene on chromosome 7q in carcinomas o f  the breast, 
prostate, head and neck, colon and ovary 4^2,344,345,346 studies have shown that the 
smallest commonly deleted region is located at D7S522. Other investigators, studying 
prostate tumours, suggested, that the putative tumour suppressor gene could be located 
around D7S480 and D7S486 Similarly in gastric and thyroid cancers the smallest 
commonly deleted region was located around D7S480
Several studies have attempted to identify the gene present in the smallest commonly 
deleted region o f 7q31.1. Early studies had suggested that c-met may have been the
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Table 2.2
Table o f  7q31 LOH studies in human cancers.
Tumour type Patient number LOH frequency Reference
Breast 231 40.5% Bieche et al 1992
Breast 31 83% Zenklusen et a l 1994
Breast 73 12.5% Lin era/ 1996
Breast 113 44% Bieche e r a /1997
Breast 683 19% Devilee et al 1997
Breast 49 20% Driouch et al 1998
Prostate 16 83% Zenklusen et a l 1994
Gastric 53 34% N ish izukae/a /1997
Colon 8 80% Zenklusen et al 1995
Thyroid 42 48% Zhang et a l 1998
Ovarian 22 50% Kioke e r a /1997
D7S440
D7S13
D7S18
D7S486
D7Sm
D7S523
D7S480
D7S650
D7S490
D7S125
D7S495
D7S5396
ABP1
D7S22
7q11.23
7q22
7q31.1
7q31.2
7q32
7q33
7q35
7q36
Figure 2.5
Microsatellite map o f  the long arm o f chromosome 7. Arrows point to the smallest 
regions o f frequent deletion as observed in human breast cancers. These are separate 
from the c-met locus at 7q31.1. DS7522 also harbours the fragile site FRA7G which 
may explain the wide variability in frequency o f LOH observed at 7q31.1.
candidate gene. Deletion mapping o f  7q31 in breast cancer has identified a lOOOkb 
deletion including c~met but no other known genes Microsatellite marker 
experiments in breast cancer observed the smallest commonly deleted region o f  7q31.1 
to be at D7S522 However, the c-met locus is situated 500kb telomeric to D7S522 
and is separate from the other frequently deleted regions D7S480 and D7S486 (Figure
2.5) In a recent series o f 113 primary breast cancers, Bieche et al reported the 
smallest commonly deleted region o f  7q31 lay between D7S480 and D7S650 which are 
telomeric to c~met Finally, mutation analysis o f  c-met in prostate cancers suggested 
the gene was rarely mutated in this disease These observations do not support c-met 
as the candidate tumour suppressor gene at 7q31.
The frequency and significance o f  LOH at 7q31 in human breast cancer has been the 
subject o f several studies. In a series o f 121 informative primary breast cancers, Bieche 
et al first reported a frequency o f  LOH at 7q31 o f  40.5% Furthermore, breast cancer 
patients with LOH at 7q31 experienced a significant reduction in both disease-free and 
overall survival. The utilisation o f polymorphic markers later located the common 
region o f  LOH to be distributed around the D7S522 probe and observed LOH in 83% o f  
31 cases Subsequent analysis using a combination o f RFLP and microsatellite 
markers in another series o f 113 primary breast cancers demonstrated LOH o f  a 
fi’equency o f 46% around D7S522 Previous independent studies using similar probes 
(3 pmet H, one JCZ67 and one pmet H/XV-2c) had reported a frequency o f  LOH at 
7q31 o f less than 10% In a series o f 73 breast cancers, Lin et al observed LOH at 
7q31 in 12.3% o f  informative cases In addition, a recent genome wide study o f 115
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primary breast cancers, looking for LOH patterns using 184 microsatellite markers, 
detected allelic loss at 7q31 at a frequency o f just below 20% Finally, a multicentre 
study o f 683 breast cancers, using three polymorphic markers for 7q31-32, detected an 
average LOH o f 19% Disease-free and overall survival o f the patients whose 
tumours carried LOH at 7q31 did not differ significantly from those that did not. This 
study, the largest to date, concluded that LOH at 7q31 was neither an important genetic 
alteration nor a strong determinant o f disease outcome in breast cancer. Recently 
members o f the Bieche group reported LOH at 7q31 at a frequency o f less than 20% in 
breast cancer patients They concluded that the involvement o f 7q31 was
controversial in breast cancer.
Several reasons can be forwarded to explain the wide range o f LOH at 7q31 reported by 
various investigators (Table 2.2). Tumour heterogeneity and inclusion o f non-malignant 
tissue may obscure allelic losses. Small sample numbers and differences in patient 
selection may be important. Observer variation may play a part. In a double blind 
analysis o f a subset o f the 683 breast cancers investigated for allelic loss at 7q31, 
Devi lee et a l observed variation in LOH scoring o f 12% Recently the presence o f  a 
chromosomal fragile site, FRA7G, has been located to D7S522 at 7q31.1 
Fluorescent in-situ hybridisation analysis o f human prostate cancers demonstrated 
FRA7G breakage throughout the D7S522 region. The presence o f  a fragile site within 
7q31.1 suggests deletions in this region may be the result o f the intrinsic instability 
rather than the presence o f a tumour suppressor gene
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The results o f the present study do not support the presence o f a tumour suppressor gene 
at 7q31.1, specifically the c-met locus, in human breast cancer. This observation has 
now been subsequently confirmed by several recent independent studies 2^,59,135,153 
possible that the wide range o f LOH observed at 7q31.1 is partly the function o f a 
naturally occurring chromosomal fragile site present at D7S522.
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Chapter 3: HGF/SF-c~met ligand receptor system in human breast cancer 
Introduction
HGF/SF is a mesenchymal derived growth factor that is active through a receptor 
encoded by c-met in a wide variety o f epithelial cell types and endothelial cells. 
Through its receptor HGF/SF promotes not only cell growth but also cell dissociation, 
motility, invasiveness and angiogenesis. This biological profile has led to the hypothesis 
that aberrant function o f  the HGF/SF-c-me? ligand receptor system may play a role in 
tumour progression in human cancers In support o f this hypothesis, aberrant 
HGF/SF-c-7we? signalling has been shown to promote both tumour invasiveness and 
metastasis in vitro and in vivo
Benign and malignant human breast epithelial cells in culture demonstrate dissociation 
and increased motility in response to HGF/SF 26>2so ^his response to HGF/SF is related 
to the degree o f  differentiation, well-differentiated cells demonstrating less motility 
when compared to poorly differentiated cells. Breast epithelial cells form lumen-like 
structures in vitro in response to HGF/SF, suggesting a possible role in morphogenesis 
These studies indicate that HGF/S¥-c-met may be involved in both physiological 
and pathological processes occurring in breast. HGF/SF expression has been detected 
by immunohistochemistry in breast tissue Furthermore, HGF/SF levels are 
significantly higher in breast cancer homogenates when compared to levels detected in 
normal breast tissue
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The expression status o f c-met in breast epithelium has been the subject o f controversy. 
Prat et al detected immunoreactive c-met in 6/25 human primary breast cancers and 0/3 
samples o f normal breast tissue whereas Di Renzo et al detected c-met mRNA in 2/2 
samples o f normal breast and 0/15 samples o f human breast cancer These studies 
based on small sample numbers require cautious interpretation. Tsarfaty et a l detected 
epithelial immunoreactive c-met in all 50 samples taken from patients with primary 
breast cancer. However, expression o f c-met was higher in adjacent tumour-free breast 
epithelial cells when compared to malignant epithelial cells
To further investigate the YiGVISV-c-met ligand receptor system in human breast cancer, 
expression o f both c-met protein and HGF/SF was determined in a series o f benign and 
malignant breast tissues. Expression o f these factors was then related to clinico- 
pathological variables, disease-free and overall survival by both univariate and 
multivariate analysis.
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Materials and methods 
Tissue samples
Samples o f archival primary breast tumour, obtained between 1987-1989, with a 
median follow-up o f 61 months, were retrieved for 73 patients that underwent definitive 
surgery for breast cancer at the Western Infirmary, Glasgow. None o f these patients had 
received preoperative cytotoxic, endocrine or radiotherapy. These samples fanned part 
o f a tumour bank, for which patient consent and ethical committee approval had been 
obtained. This consisted o f  tissue samples packaged in aluminium foil, snap frozen and 
stored in liquid nitrogen. Clinico-pathological variables (age, axillary nodal status, 
tumour size, histological grade, oestrogen receptors and vascular invasion), disease- 
relapse and survival data were obtained from patient casenotes. In addition, 10 samples 
o f  tumour-free breast tissue were obtained (nine samples from patients undergoing 
mastectomy and one sample o f  breast tissue from a reduction mammoplasty). In the 
case o f  tissues obtained at mastectomy, samples were both macroscopically and 
histologically free from the presence o f  tumour.
Cell line
The HT29 colonic carcinoma cell line was used as a positive and quality control for the 
detection o f  c-met protein The cells were grown at 37^C in RPMl 1640 medium 
supplemented with 10% foetal calf serum in a 5% COa-water saturated atmosphere until 
confluent.
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Tissue preparation
HT29 colon carcinoma cell lines
The cells were washed twice with phosphate buffered saline (PBS)/EDTA and 
incubated with trypsin/EDTA for 10 minutes at room temperature. This was centrifuged 
at 1000 rpm for 5 minutes and the supernatant discarded. The cells were washed with 
PBS and centrifuged again at 1000 rpm for 5 minutes. The resultant cell pellet was 
dissolved in lysis buffer (2mM Tris (pH 7.5), 50mM NaCl, 0.5% (w/v) sodium 
deoxycholate, 1% (v/v) Nonindet P-40, 0.1% (w/v) SDS, ImM phenylmethyl-sulphonyl 
fluoride, 1 mg/ml aprotinin) This was centrifuged for 15 minutes at 12000g and the 
supernatant aliquoted and stored at -70^C.
Breast tissue samples
Blocks measuring 5mm^ were cut from the frozen tumour samples for homogenisation. 
The remaining sample was stored at -70^C for further immunohistochemical studies. 
Haematoxylin and eosin (H&E) sections were also prepared from these samples to 
confirm presence o f tumour. Tissues were ground into a powder using a pestle and 
mortar in liquid nitrogen. The powder was then dissolved in 0.25ml o f  lysis buffer. This 
was centrifuged for 15 minutes at 12000g and the supernatant aliquoted and stored at - 
70^C.
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Protein concentration
The protein concentrations o f  tissue homogenates were measured using the Pierce BCA 
protein assay kit (Pierce, Illinois, USA). This assay is based on the reaction o f  protein 
with Cu^ "*" to yield Cu^ which forms a purple coloured complex with bichinchoninic 
acid. This reaction is protein concentration dependent allowing spectrophotometric 
quantitation at 562nm. Protein standards o f  known concentration (200pg/ml- 
1200jug/ml) were prepared by dilution o f bovine serum albumin (BSA). To 0.1ml o f  
either standard or unknown protein, 2.Omis o f  Working Reagent was added and the 
mixture incubated for 2 hours at room temperature. Absorbance was measured at 
562nm against a water blank. A standard curve was then plotted for the absorbance o f  
protein standards and protein concentration o f samples determined from this.
Discontinuous SDS-polvacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was conducted using a MINI-PROTEAN II Dual slab gel apparatus (Bio- 
Rad, Hertfordshire, UK, Figure 3.1). Protein electrophoresis was conducted using a 
7.5% gel for c-met and a 12% gel for HGF/SF.
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Figure 3.1
Photographs o f Biorad MINI-PROTEAN II Dual slab gel apparatus (above) and Biorad 
Mini Trans-Blot electrophorestic transfer cell (below). Lower buffer chamber and lid 
(A), casting stand (B), inner cooling core (C), sandwich clamp assemblies (D), casting 
alignment card (E)
Preparation o f gels 
Assembling glass plates
Glass plates were washed in distilled water and polished with methanol prior to 
assembly. The outer and inner glass plates were separated using 0.5mm thick spacer 
bars and then fixed in the gel clamp assembly. These were then connected to the casting 
stand.
Casting the gels
Discontinuous polyacrylamide gels consisted o f resolving or separating (lower) gels and 
stacking (upper) gels. Molecules were separated in the resolving gels using the Laemmli 
discontinuous buffer system. The running gel was prepared as below. The gel was 
allowed to polymerise for 1 hour and the iso-butanol removed. The top o f  the gel was 
then washed with distilled water and dried using a filter paper.
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Running gel Q.375M Tris. pH 8.8
Reagent 12% gel 7.5% gel
Distilled water 3.35ml s 4,85mls
1.5M TrisHCL,pH8.8 2.5mls 2,5mls
10% SDS lOOpl lOOpl
Acrylamide/Bis (30%) 4mls 2.50mls
10% fresh NH^ Persulphate 50|l i 1 50pl
Tetramethylethylenediamine (TEMED) 5pl 5 pi
The stacking gel was prepared and poured between glass plates on
gel. A  ten toothed comb (0.5cm spacing) was then placed into the running gel which 
was allowed to set for 1 hour.
Stacking Gel 4%. 0 .125M Tris, pH 6.8
Distilled water 
1.5M TrisHCL,pH8.8  
10% SDS 
Acrylamide (30%)
10% fresh NH"^  Persulphate 
TEMED
6.1 mis
2.50mls
lOOpl
l.Smls
50jal
5pl
The comb was then removed and wells washed with distilled water and dried in filter 
paper.
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Assembling the electrophoresis cell
The clamp assemblies/gel sandwiches were released from the casting stand and then 
clamped onto the inner cooling core. This was lowered into the lower buffer chamber o f  
the Mini-PROTEAN II cell. 300mls o f electrode buffer (5x electrode buffer pH 8.3: 
9gms Tris-base, 43.2gms glycine, 3gms SDS made up to 600mls with distilled water) 
was prepared. Approximately 115mls was then added to the upper chamber and the rest 
to the lower chamber.
Sample preparation
Samples were thawed slowly on ice. Appropriate volumes containing lOOpg total 
protein were freeze dried, diluted with lOpl o f  reducing sample buffer (4mls distilled 
water, 1ml 0.5M Tris-HCL pH 6.8, 0.8ml glycerol, 1.6mls 10% SDS, 0.2ml 0.05% 
bromophenol blue, 50pl/ml mercaptoethanol) and boiled for two minutes. Gels were 
then loaded: lane 1 - molecular weight markers (Sigma, Dorset, UK), lane 2 - positive 
control, lanes 3 to 7 - breast tissue homogenates. Gels were electrophoresed for 1 hour 
at 20mA.
Protein transfer
Separated proteins were transferred to a nitrocellulose membrane using the Mini Trans- 
Blot electrophoretic transfer cell (Bio-Rad). Millipore nitrocellulose membrane
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(Millipore, Bedford, UK) and 4 squares o f  3MM paper were cut to the same size as the 
gel. The membrane was first soaked in methanol and then washed with distilled water. 
The membrane, paper and sponges soaked in transfer buffer (2.52gms sodium 
bicarbonate, 0.954gm sodium carbonate, 600rals industrial ethanol, 2.4L distilled water) 
for 30 minutes. The gel holder cassette was assembled incorporating gel and membrane. 
This was placed in the buffer tank and filled with transfer buffer. The assembly was 
placed in ice and run at lOOkV, 400mA, 300W for 1 hour.
Immunostaining o f membranes
Membranes were blocked using 5% non-fat dry milk (Marvel) diluted with 0.1% Tween 
20 (polyoxyethylenesorbitan) for 1 hour. This was washed three times in Tris buffered 
saline (TBS) and the primary c-met specific antibody, 19S, was added (donated by Dr. 
G.F. Vande Woude, NCI, Frederick, USA). This antibody is monoclonal and raised 
against a 50kDa protein (p50met) from the carboxy-terminal part o f the human c-met 
protein The antibody was used at a concentration o f 1/1000 diluted in PBS/0.1%  
Tween 20 and incubated at room temperature overnight The membrane was washed 
three times in PBS/0.1% Tween 20 for 10 minutes. A secondary alkaline phosphatase 
coupled rabbit anti-mouse antibody (Dako, Glostrup, Denmark) was added at a 
concentration o f  1/1000 diluted in PBS/0.1% Tween 20 and incubated at room 
temperature overnight. Membranes were washed twice in PBS/0.1% Tween 20 and then 
once in TBS pH 9.5 for 10 minutes. Bound antibody was visualised by a chromogenic 
reaction catalysed by the conjugated alkaline phosphatase using nitroblue tétrazolium
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and 5-bromo-4-chloro-3-indoyl phosphate as chromogenic substrate. C-met expression 
was then visually assessed by an independent observer.
Controls
Controls included incubation o f membrane without primary antibody and incubation 
with primary antibody which had been preincubated for 1 hour at room temperature 
with the competing peptide pmet 50 (Ipg  peptide per 1|l i 1 antibody. Dr.G.F. Vande 
Woude).
HGF/SF expression bv enzvme linked-immunosorbent assav (ELISA)
HGF/SF levels in breast tissue homogenates were measured using a sandwich type 
ELISA developed between University Department o f  Pathology, University o f  Glasgow  
and Genentech Inc., San Francisco, USA. 96 microwell plates were coated with A3.1.2 
HGF/SF specific mouse monoclonal antibody (Genentech Inc.) diluted in 0.5M sodium 
carbonate/0.5M sodium bicarbonate buffer at a concentration o f 5ng/ml (lOOpl per well) 
and incubated for 16 hours at room temperature. The plate was washed six times with 
0.05% Tween 20 in PBS and then blocked with 0.5% BSA/0.5% Tween 20 in PBS for 
two hours at room temperature. After washing six times with 0.05% Tween 20 in PBS 
each well was coated with SOpl o f  either test samples or standard concentrations o f  
recombinant HGF/SF (Genentech Inc.) and incubated for 2 hours at room temperature. 
The plate was washed six times with 0.05% Tween 20 in PBS and each well coated
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with sheep polyclonal anti-HGF/SF antibody (Genentech Inc.) at a concentration o f  
1/5000 in 0.5% BSA/PBS and incubated at room temperature for 1 hour. The plate was 
washed in 0.05% Tween 20 in PBS and each well coated with biotinylated donkey anti­
sheep antibody (ICN Biomedicals, Thame, UK) at a concentration o f 1/5000 in 0.5% 
BSA/PBS and incubated for 1 hour at room temperature. The plate was washed with 
0.05% Tween 20 in PBS and then each well was coated with Avidin-Horseradish 
Peroxidase Conjugate at a concentration o f 1/6000 and incubated for 1 hour at room 
temperature. The plate was washed six times with 0.05% Tween 20 in PBS and each 
well coated with 0-phenylenediamine in 0.2M citric acid/potassium hydroxide at pH 5 
with 25|ul o f concentrated hydrogen peroxide added immediately before use. The 
reaction was then stopped by the addition o f  2M sulphuric acid. The plate was read 
using an automated microplate optical colometric densitometer at 492nm. Samples o f  
tissue homogenate and standard dilutions o f HGF/SF were analysed either in duplicate 
or triplicate. HGF/SF concentrations were then read from a curve derived from HGF/SF 
standards (Figure 3.2). Serial dilutions o f  homogenates were performed in subsequent 
assays to ensure results lay within the linear part o f the standard curve. The lower 
detection limit o f  this assay was 0.25ng/ml (intra-ELISA variation: 1-5%, mean 2%). 
The HGF/SF concentrations were then converted to nanogrammes (ng) per lOOmg o f  
total protein.
71
Ec
CM
8c
Io
(0
1.8
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
0 2.5 5 7.5 10
HGF/SF (ng/ml)
Figure 3.2
Typical HGF/SF standard curve. Absorbance at 492 nm (y axis), HGF/SF concentra­
tion in ng/ml (x axis).
A3.1.2 and sheep anti-HGF/SF specificity
Antibodies A3.1.2 and polyclonal sheep anti HGF/SF were checked for specificity and 
for cross reaction in breast cancer samples by Western blot electrophoresis on 12% 
polyacrylamide gels. Western blots o f reduced samples o f human recombinant HGF/SF 
and breast cancers were prepared. Membranes containing reduced HGF/SF were 
incubated overnight individually with A3.1.2 (1/2500) in PBS/0.1% Tween 20, sheep 
anti-HGF/SF (1/1000) in PBS/0.1% Tween 20 or preincubated antibody at room 
temperature. Preincubated antibodies were prepared by combining excess human 
recombinant HGF/SF (lOpg) with either A3.1.2 (1/2500) or sheep anti-HGF/SF 
(1/1000) in PBS/0.1% Tween 20 overnight at room temperature. In addition non- 
specific protein binding by the A3.1.2 and sheep anti-HGF/SF antibodies were 
examined in six breast cancer samples by Western blot electrophoresis. Membranes 
treated with A3.1.2 were incubated with a secondary alkaline phosphatase coupled 
rabbit anti-mouse antibody (Dako, Glostrup, Denmark) at 1/10,000 in PBS/0.1% Tween 
20 for 1 hour after washing. Membranes treated with sheep anti-HGF/SF were 
incubated with a secondary rabbit anti-sheep alkaline phosphatase coupled antibody 
(Dako, Glostrup, Denmark) at 1/5000 for 1 hour. Membranes were washed twice in 
PBS/0.1% Tween 20 and then once in TBS pH 9.5 for 10 minutes. Bound antibody was 
visualised by a chromogenic reaction catalysed by the conjugated alkaline phosphatase 
using nitroblue tétrazolium and 5 -bromo-4-chloro-3 -indoyl phosphate as chromogenic 
substrate.
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Statistical analysis
The relationship between HGF/SF, prognostic factors and disease-relapse or overall 
survival could not be regarded as normally distributed and non-parametric statistical 
analysis was applied. They were tested by Mann-Whitney or Kruskal-Wallis tests for 
categorical prognostic factors or by Spearman's rank correlation for continuously 
variable prognostic factors. The relationship between c~met expression and clinico- 
pathological variables were tested using Chi-square or Mann-Whitney tests. The 
multivariate relationships between prognostic factors and disease-relapse were tested by 
analysis o f variance and covariance,
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Results (appendix 1)
C-met expression in non-malignant breast tissues and in breast cancer 
Confirmation o f antibody efficacy
Reduced c-met protein on Western blot electrophoresis is characterised by two protein 
bands o f  170 and 145 kDa, with the 145 kDa band being the most prominent (170kDa 
band corresponding the precusror o f  p i45 Met and the 145kDa band corresponding to 
the P-chain o f  the c-met receptor, p i 45 Met) Western blot analysis o f  the HT29 colon 
carcinoma cell line known to express c-met demonstrated the expected protein bands 
when using the 19S antibody (Figure 3,3). Incubation o f  the antibody with its 
competing peptide completely abolished binding to these proteins thus confirming 
specificity (Figure 3.3).
C-met expression in benign breast tissue
Ten samples o f  histologically proven benign breast tissue specimens were analysed for 
c-met expression. All samples demonstrated the two protein bands corresponding to c- 
met protein (Figure 3.4),
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Figure 3.3
Western blot demonstrating c-met protein bands in HT 29 positive control. Lane 1: 
molecular weight markers. Lane 2: reduced HT 29 control. Two protein bands of 170 
and 145 kDa are detected by 19S monoclonal antibody. Lane 3: Incubation of 19S 
antibody with its competing peptide completely abolishes binding to c-met proteins.
170 kDa 
145 kDa
Figure 3.4
Representative Western blot of c-met protein in tumour-free breast tissue. Lane 1: HT 29 
positive control. Lanes 2, 4 and 6; tumour-free breast tissue. Two c-met specific bands (pl45 
met and p i70 met) were detected as labelled. Lanes 3 and 5 were blank.
C-met expression in breast cancer
C-met protein was detected in only 26 (36%) breast cancers, whereas in the remaining 
47 (64%) breast cancers it was either absent or barely detectable (Figure 3.5). The 
relative levels o f  c-met expressed, comparing benign to malignant, could not be 
assessed by this method.
HGF/SF expression in non-malignant breast tissues and in breast cancer
Confirmation o f  antibody specificity and exclusion o f cross-reactivitv with tissue 
homogenates
Antibodies A3.1.2 and polyclonal sheep anti-HGF/SF were checked for specificity by 
Western blot electrophoresis o f  human recombinant HGF/SF. Both antibodies 
recognised the 69kDa heavy chain component o f  HGF/SF (Figure 3.6 and 3.7). 
Incubation o f both antibodies with human recombinant HGF/SF eliminated binding to 
HGF/SF thus confirming antibody specificity (Figure 3.6 and 3.7), Absence o f  cross- 
reactivity between these antibodies and other tissue proteins was examined by Western 
blot analysis o f several breast cancer homogenates. The A3.1.2 antibody demonstrated a 
high level o f specificity and no cross reaction with other proteins confirming suitability 
for use as primary antibody for ELISA (Figure 3.8).
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Figure 3.5
Representative Western blot of c-met protein in breast cancers. Lane 1: HT29 positive 
control. Lanes 2-7: breast cancers. Lanes 6 and 7: breast cancers with detectable c-met 
protein. Lanes 2, 3, 4 and 5: breast cancers with absent or barely detectable c-met protein. 
Two c-met specific bands (pl45 met and p 170 met) were detected.
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Figure 3.6
Western blot demonstrating 69 kDa band of reduced human recombinant HGF/SF detected by 
A3.1.2 monoclonal antibody. Lane 1: molecular weight markers. Lane 2: reduced HGF/SF. 69 
kDa band corresponding to a-chain seen. Lane 3: pre-incubation of A3.1.2 with HGF/SF 
abolishes binding to HGF/SF a-chain thus confirming antibody specificity.
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Figure 3.7
Western blot demonstrating 69 kDa band of HGF/SF derived from MRC-5 fibroblasts 
detected by sheep polyclonal HGF/SF antibody(Genentech). Lane 1: molecular 
weight markers. Lane 2: reduced HGF/SF. 69 kDa band corresponding to a-chain of 
HGF/SF. Lane 3: pre-incubation o f sheep polyclonal HGF/SF antibody with HGF/SF 
reduces binding to HGF/SF a-chain. Other protein bands are also seen in lanes 2 & 3. 
This antibody was used to detect HGF/SF bound to A3.1.2 in ELISA and would not 
be suitable for use as primary antibody.
69 kDa
Figure 3.8
Western blot of breast cancer homogenates with A3.1.2 monoclonal antibody 
(Genentech). Lane 1: molecular weight markers. Lane 2: reduced HGF/SF demonstrating 
69 kDa a-chain. Lanes 3-8: reduced breast cancer homogenates. No protein bands 
detected. Although breast cancer homogenates contain HGF/SF as detected by ELISA, 
levels may be too low to detect by Western blot. However, this experiment provides some 
evidence of A3.1.2 specificity and absence o f cross-reactivity with other protein species.
HGF/SF levels in breast cancer and tumour-free breast tissue
HGF/SF was detected in all samples o f  tumour-free breast tissue and in 71 breast 
cancers. The remaining two breast cancer samples were insufficient for duplicate or 
triplicate ELISA analysis. The concentration o f HGF/SF was significantly higher in 
breast cancers (range 58-1604ng per lOOmg total protein; mean; 396ng per lOOmg total 
protein) than tumour-free breast tissue (range 66-200ng per lOOmg total protein; mean: 
130ng per lOOmg total protein), p<0.001, Figure 3.9.
Prognostic significance o f c-met and HGF/SF in breast cancer
Patient data
Clinico-pathological prognostic variables from 73 patients with breast cancer are 
summarised (Table 3.1). The median follow-up was 61 months (range 7-89 months). 
Local recurrence was observed in three patients, local and systemic recurrence in nine 
patients and systemic recurrence in 16 patients. All patients with systemic recurrence 
died from metastatic disease. Positive nodal status correlated with disease-relapse 
(p=0.013) and reduced overall survival (p=0.024), (Table 3.2). Tumour size correlated 
with disease-relapse (p=0.027), (Table 3.2). The remaining prognostic clinico- 
pathological variables did not correlate with either disease-relapse or overall survival 
(Table 3.2).
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Figure 3.9
Scatterplot comparing HGF/SF levels in tumour-free breast tissue and breast 
cancers.
* statistically significant (Spearman’s rank correlation)
Table 3.1
Clinico-pathological prognostic variables o f 73 patients with breast cancer.
Prognostic variables n
Age (years)
<55 28
^55 45
Tumour size (mm)
<25 26
>25 47
Lymph node status*
Positive 36
Negative 33
Tumour Grade **
1 8
2 31
3 27
Oestrogen receptor status***
Positive 29
Negative 32
Lymphatic Invasion
Present 21
Absent 52
* Lymph node status unknown in 4 patients
** Tumours not graded (4 lobular, 2 mucoid, 1 medullary)
*** Oestrogen receptor status unknown in 12 patients
Table 3.2
Categorical prognostic factors and tests o f their relationship with disease-free and overall 
survival. The prognostic value o f  dichotomous factors {c-met expression, nodal status, 
tumour size, oestrogen receptor, lymphatic invasion) were tested by the Mann-Whitney 
test and the prognostic value o f histological grade was tested by the Kruskal-Wallis test. 
Continuously variable prognostic factors: HGF/SF, age and tumour size were tested by 
Spearman’s rank correlation coefficient corrected for ties.
Prognostic
factor
Values n Median
Relapse-free
survival
(months)
P
value
Median
overall
survival
(months)
P
value
c-m et Negative 47 >60 0.012 >60 0.080
Positive 26 42.5 60
Nodal status Negative 33 >60 0.013 >60 0.024»
Positive 36 46 60
Histological 1 8 >60 0.369 >60 0.205
grade 2 31 >60 >60
3 27 >60 >60
Oestrogen Negative 31 >60 0.262 >60 0.238
receptor Positive 30 >60 >60
Lymphatic Negative 52 >60 0.427 >60 0.472
invasion Positive 21 >60 >60
Prognostic
factor
n Correlation 
to disease- 
free 
survival
p value Correlation 
to overall 
survival
p value
HGF/SF 71 -0.4916 <0.001 -0.4258 <0.001*
Age (years) 73 -0.1185 0.318 -0.0645 0.588
Tumour size 
(mm)
73 -0.2597 0.027 -0.1862 0.115
statistically significant
HGF/SF levels not available in 2 patients 
Lymph node status unknovm in 4 patients 
Tumours not graded (4 lobular, 2 mucoid, 1 medullary) 
Oestrogen receptor status unknown in 12 patients
HGF/SF and c-met expression in breast cancer 
Univariate analysis
HGF/SF concentrations demonstrated significant correlation with both disease-relapse 
and overall survival in patients with breast cancer. Levels in patients with disease- 
relapse (median 502ng/100mg total protein) were significantly higher than those who 
remained disease-free (median 297ng/100mg total protein), p<0.001, (Figure 3.10). 
Similarly, HGF/SF levels were significantly increased in patients who died from disease 
progression (median 513ng/100mg total protein) when compared to survivors (median 
313ng/100mg total protein), p<0.001, (Figure 3.11). There was a non-significant trend 
between increasing HGF/SF levels and poorer histological grade (Figure 3.12). 
However, HGF/SF levels did not show any correlation with nodal status, tumour size, 
oestrogen receptor status and lymphatic invasion (Table 3.3). HGF/SF levels appeared 
to be higher in tumours expressing c-met {c-met negative: median 330ng/100mg total 
protein; c-met positive: median 407ng/100mg total protein).
The statistical relationships between c-met expression, survival and clinico-pathological 
variables are summarised (Tables 3.2 and 3.4). Breast cancers with detectable c-met 
protein demonstrated a significant association with disease-relapse, p=0.012, (Figure 
3.13). There were non-significant associations between c-met with reduced survival, 
p=0.080, (Figure 3.14) and c-met with lymphatic invasion (p=0.057). There were no 
significant relationships between c-met, nodal status, tumour grade, tumour size and
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Figure 3.10
Comparison o f  tumour HGF/SF levels in patients with disease-relapse to those remaining 
disease-free.
* statistically significant (Mann-Whitney)
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Comparison o f  HGF/SF levels with survival in patients with breast cancer. 
* statistically significant (Spearman’s rank correlation)
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Figure 3.12
Comparison o f  tumour HGF/SF levels with histological grade in patients with breast cancer 
(p=0.44, Kruskal-Wallis).
Table 3.3
Categorical prognostic factors and tests o f their relationship with HGF/SF. The 
relationship o f nodal status, oestrogen receptor and lymphatic invasion to HGF/SF was 
tested by the Mann-Whitney test. The relationship o f  histological grade to HGF/SF was 
tested by the Kruskal-Wallis test. Continuously variable prognostic factors, age and 
tumour size, were tested by Spearman’s rank correlation coefficient corrected for ties.
Prognostic
factor
Values n Median 
HGF/SF level
p value
Nodal status Negative 33 378.0 0.99
Positive 36 350.0
Histological 1 8 252.5 0.44
grade 2 31 345.0
3 27 370.0
Oestrogen Negative 31 374.0 0.87
receptor Positive 30 388.0
Lymphatic Negative 52 338.0 0.53
invasion Positive 21 370.0
Prognostic factor n Correlation with  
HGF/SF
p value
Tumour size 71 0.024 0.84
Age 71 0.071 0.54
HGF/SF levels not available in 2 patients 
Lymph node status unknown in 4 patients 
Tumours not graded (4 lobular, 2 mucoid, 1 medullary) 
Oestrogen receptor status unknown in 12 patients
Table 3.4
Categorical prognostic factors and tests o f  their relationship with c~met. The relationship 
o f  nodal status, tumour grade, oestrogen receptor and lymphatic invasion to c~met status 
was tested by the Chi-squared test with Yates modification. The relationship between c- 
met to age and tumour size was tested using the Mann-Whitney test.
Variable n Number c-met 
negative
Number c-met 
positive
P
value
Nodal status Negative 24 9 2.197 0.14
Positive 20 16 1 df
Tumour grade 1 5 3 0.017 0.76
2 19 12 2df
3 12 8
Oestrogen Negative 18 11 0.136 0.86
receptor Positive 20 10 Idf
Lymphatic Negative 37 15 3.613 0.057
invasion Positive 10 11 Idf
Prognostic Values n Median age p value
factor
Age c~met negative 47 62 0.52
c-met positive 26 56
Prognostic Values n Median p value
factor tumour size
Tumour size c-met negative 47 28 0.89
c-met positive 26 30
Lymph node status unknown in 4 patients 
Tumours not graded (4 lobular, 2 mucoid, 1 medullary) 
Oestrogen receptor status unknown in 12 patients
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Figure 3.13
Graph o f  relationship between c-met expression and disease-relapse in patients with breast 
cancer (p=0.012, Mann-Whitney).
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Figure 3.14
Graph of relationship between c-met expression and overall survival in breast 
cancer (p=0.08, Mann-Whitney).
oestrogen receptor status.
Relationship between HGF/SF. c-met. prognostic variables and disease-relapse
Non-linear discriminant analysis combined with analysis o f variance and covariance 
suggested a statistical interaction between HGF/SF and c-met in relation to disease- 
relapse (appendix 3). Non-linear discriminant analysis was carried to predict disease- 
free survival. Initially the variables; age, size, grade, nodal status, oestrogen receptor 
status, lymphatic invasion, c-met, HGF/SF and the combined tenn HGF/SF*c-we/^ were 
considered for inclusion in the model. Using Wilks’ lambda method, these prognostic 
indicators were tested for any statistically significant contribution to the accuracy o f  
prognosis. Only three prognostic factors satisfied entry into the model; HGF/SF*c-mer 
(p=0.0001), HGF/SF (p<0,001) and nodal status (p<0.001). Importantly, the effect o f  c- 
met independent o f  HGF/SF became statistically non-significant in relation to disease- 
relapse. This suggests that the observed effect o f  c-met on disease-relapse is wholly 
dependant on the presence o f  HGF/SF.
In the analysis o f  variance and covariance, the prognostic variables; age, tumour size 
and grade, nodal status, oestrogen receptors, lymphatic invasion, HGF/SF and c-met 
were tested for the statistical significance o f  their relationship to disease-relapse. Any 
insignificant terms were removed from the model sequentially. On introduction o f the 
HGF/SF'’'c-me/ interaction term, the effect o f  c-met became insignificant. In this model, 
the most significant predictors o f  disease-relapse were HGF/SF (p<0.001) and the
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interaction o f HGF/SF and c-met (p=0.014). Other predictors o f disease-relapse were 
tumour size (p=0.037) and nodal status (p=0.054).
These multivariate analyses demonstrate a significant statistical interaction between 
HGF/SF and c-met in relation to disease-relapse. When this interaction (HGF/SF*c-we/) 
is added to the above models, the direct effect o f c-met alone became insignificant 
suggesting the effects o f c-met are entirely due to HGF/SF. Therefore this observation 
provides strong support o f a ligand-receptor interaction promoting disease-progression 
in human breast cancer.
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Discussion
Aberrant HGF/SF-c-me/ expression has been shown to induce tumour invasion and 
metastasis both in vitro and in vivo. This study provides support for this hypothesis in 
human breast cancer. Multivariate analysis demonstrated a statistically significant 
interaction between HGF/SF and c-met in relation to disease-relapse. In addition, 
HGF/SF levels were increased in breast cancer and tumour levels o f HGF/SF correlated 
with disease-relapse and reduced survival. Furthermore, breast cancers with detectable 
c-met demonstrated a significant correlation with disease-relapse.
HGF/SF levels are increased in both breast cancer homogenates and in sera o f  patients 
with breast cancer 294.331,332,335 this study we observed significantly increased 
HGF/SF levels in breast tumour homogenates when compared to tumour-free breast 
tissue, Tumour levels o f HGF/SF correlated with significant reduction in both disease- 
free and overall survival. These results have been confirmed by other studies. 
Yamashita et a l observed that HGF/SF levels were significantly increased in breast 
cancer samples when compared to normal tissue Furthermore, a powerful 
correlation between increased HGF/SF levels and reduction in disease-free and overall 
survival was observed in a study o f  248 patients with breast cancer In addition, 
HGF/SF levels only correlated to tumour size and were otherwise independent o f other 
prognostic factors. Similarly, Yao et a l observed HGF/SF levels were significantly 
increased in breast cancers when compared to normal breast tissue In their study 
node positive breast cancers expressed significantly higher levels o f  HGF/SF when
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compared to node negative disease and HGF/SF levels were also related to tumour size. 
Serum levels o f  HGF/SF are also increased in breast cancer patients. Taniguchi et a l 
detected significantly increased HGF/SF levels in 36.6% o f breast cancer patients 
This observation was confirmed by Toi et a l who also observed that increased levels o f  
HGF/SF correlated with axillary nodal status and evidence o f  venous invasion 
Circulating levels o f HGF/SF decreased when primary tumour was removed suggesting 
that the observed elevated HGF/SF level was tumour-related .
Detectable c-met in breast cancer is associated with poorer prognosis. This study has 
demonstrated a significant reduction in disease-free survival in breast cancers with 
detectable c-met protein. This observation has been confirmed by Ghoussoub et a l who 
reported that tumour expression o f c-met correlated with a significant reduction in 5 
year survival in patients with breast cancer This association was seen in both node 
negative and node positive groups. Multivariate analysis demonstrated that c-met 
expression was an independent predictor o f  survival.
Expression o f c-met protein appears to be reduced in the majority o f  breast cancers 
when compared to tumour-free breast tissue. In this study c-met was detected in all 
samples o f tumour-free breast tissue. However, c-met was barely detectable or absent in 
the majority o f breast cancers. This observation is similar to Tsarfaty et a l who 
observed higher levels o f c-met expression in adjacent tumour-free ductal breast 
epithelium when compared to tumour Furthermore, Ghoussoub et a l detected 
moderate-to-intense c-met expression in normal ductal breast epithelium where only
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22% of 91 breast cancers expressed c-met These observations suggest that c-met 
expression is down-regulated in a large proportion o f breast cancers. A reciprocal 
relationship between HGF/SF and c-met expression may exist in normal breast tissue 
and breast cancers. Normal breast tissue is characterised by low levels o f  HGF/SF 
expression and high levels o f c-met. However, the majority o f  breast cancers exhibit 
high levels o f HGF/SF and low levels o f  c-met expression. HGF/SF has been observed 
to down-regulate c-mei expression in primary fibroblast cell cultures via an 
extracellular-autocrine pathway It is possible that increased levels o f  HGF/SF in 
breast cancers in vivo down-regulate c-met expression in well differentiated but not in 
poorly differentiated cancers. This hypothesis is supported by the observation that in 
vitro c-met expression is low in well differentiated and high in poorly differentiated 
breast cancer cell lines However this series failed to detect any relationship between 
c-met expression and tumour grade (p=0.76, Table 3.3).
Although the biological actions o f HGF/SF are transduced through c-met, this is the first 
study to report a relationship between this ligand-receptor pair in relation to disease 
progression. Studies both in vitro and in vivo have shown that HGF/SF activation o f c- 
met is both tumorigenic and a promoter o f  tumour invasion and metastasis The 
results o f  this study provide strong support for the hypothesis that aberrant HGF/SF-c- 
met expression plays a role in disease progression in breast cancer. Multivariate analysis 
demonstrated a statistically significant interaction between HGF/SF and c-met 
expression in relation to disease-relapse. This observation suggests that breast cancer 
progression may in part be due to ligand-driven tumour invasion and metastasis through
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HGF/SF-c-7?2er. The implications o f these findings are not only o f  prognostic utility, 
antagonism o f HGF/SF-c-we^ may have therapeutic benefits.
In vitro studies suggest a paracrine mode o f interaction between HGF/SF and c-met. 
Fibroblasts derived from breast tissue appear to produce HGF/SF whereas breast 
epithelial cells in culture do not express HGF/SF ^^ ’^ 68,280 jjowever, studies in vivo 
observe HGF/SF expression in both epithelial and stromal components o f breast tissue. 
Wang et a l detected HGF/SF mRNA by in-situ hybridisation mainly in the epithelial 
component o f normal and malignant breast tissues Tuck et a l observed HGF/SF in 
both epithelial and stromal components o f breast cancers whereas c-met expression was 
restricted to epithelial cells, using both in-situ hybridisation and immuno-histochemical 
techniques In addition, tumour cells that were strongly positive for HGF/SF were 
also strongly positive for c-met suggesting a possible autocrine loop effect. Finally, 
Ghoussoub et a l detected c-met staining in epithelial component o f both normal breast 
and breast cancers These studies show that HGF/SF-c-7we/ may function in either 
autocrine or paracrine modes. Studies o f HGF/SF-c-mg/ expression in embryogenesis 
suggest the physiological mode o f interaction is paracrine
Autocrine HGF/SF-c-^g/ expression is both highly tumorigenic and a powerful inducer 
o f tumour invasion and metastasis. The creation o f HGF/SF-c-?we^ autocrine loops in 
transgenic mice has been shown to induce a variety o f tumours with mammary glands 
being the most prevalent site Meiners et a l transfected HGF/SF cDNA into the 
human MDA MB 435 mammary carcinoma cell line and then injected these into the
83
mammary fat pads o f nude mice Non-transfected cells failed to metastasise whereas 
transfected breast cancer cells demonstrated strong growth and spontaneous metastasis 
to lung. Autocrine activation o f HGF/SF-c-me? may therefore represent an important 
pathological step in tumour metastasis.
There is mounting evidence that HGF/SF-c-we? plays a central role in breast duct 
development. The possibility o f  HGF/SF being associated with breast ductal 
morphogenesis was suggested by Tsarfaty et a l who observed breast cancer cells in 
culture forming lumen-like structures when exposed to the factor Berdichevsky et a l 
demonstrated fibroblast induced branching morphogenesis o f human mammary cells in 
collagen gels The factor responsible for this effect was identified as HGF/SF. In their 
report, factors such as acidic FGF, basic FGF and PDGF had no effect on ductal 
morphogenesis, whereas TGF-p inhibited HGF/SF induced branching. Similar findings 
were reported by Soriano et al, who identified HGF/SF as the fibroblast derived factor 
inducing ductal branching and lumen formation in murine mammary cells cultured in 
collagen gels HGF/SF was observed to increase cord length 11-22 times more 
potently than TGF-a and EGF. IGF-II, basic FGF and PDGF had no such effect and 
again TGF-P inhibited HGF/SF induced ductal morphogenesis. Systemic hormones 
such as oestrogen, progesterone, insulin and prolactin were not observed to induce 
branching morphogenesis. Although these factors are essential to breast development, 
final expression o f their signal may require interaction o f stromal cells through 
production o f local factors. Yang et a l demonstrated that HGF/SF promoted branching 
morphogenesis in post-natal mouse mammary organ cultures Finally, Niranjan et a l
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demonstrated HGF/SF induced branching morphogenesis in human mammary 
organoids embedded in collagen gels HGF/SF levels in developing breast appear to 
be strongly regulated. Yang et a l observed high levels o f  HGF/SF expression during 
ductal morphogenesis in virgin mice, expression decreasing during pregnancy and 
lactation and increasing again during involution These observations were confirmed 
by Niranjan et a l who detected HGF/SF in addition to c-met expression during mouse 
mammary gland development
In conclusion, HGF/SF and c-met are important factors involved in both breast duct 
development and in tumour progression in breast cancer. This study provides evidence 
o f a statistically significant interaction between HGF/SF and c-met in relation to 
disease-relapse. It is not known whether ligand-receptor interactions switch from 
paracrine to autocrine in tumour cells that undergo metastasis. However, autocrine 
HGF/SF-c-mer loops in vivo strongly promote métastasés in experimental systems. 
Agents that interfere with HGF/SF-c-we^ interactions may provide important new 
therapeutic agents in breast cancer treatment.
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Chapter 4: Hepatocvte growth factor/scatter factor, angio genesis and 
tumour cell proliferation in primary breast cancer
Introduction
Proliferation and angiogenesis are important prognostic variables in breast cancer. 
However, little is known regarding the intrinsic and extrinsic factors that control these 
variables. In breast cancer growth factors such as basic FGF, PDGF, TGF-a, VEGF, 
growth factor receptors to EGF and PDGF and the growth inhibiting factor TGF-p may 
be implicated HGF/SF expression is increased in human breast cancer. In vitro 
studies have shown that HGF/SF stimulates cell growth, dissociation, motility and 
invasiveness in a wide variety o f epithelial cell types including breast 244,247,250 
Treatment o f  EMT6 mouse mammary tumour cells with HGF/SF stimulates invasion 
through matrigel, expression o f soluble and cell surface urokinase and lung colonisation 
HGF/SF is also a potent inducer o f angiogenesis with a nanogram potency similar to 
basic fibroblast growth factor Bussolino et a l demonstrated human endothelial cell 
proliferation and motility in vitro and neovascularisation at sub-nanomolar 
concentrations in the rat cornea Grant et a l similarly demonstrated HGF/SF induced
vascular endothelial cell migration, proliferation and organisation into capillary-like 
tubes in vitro. Furthermore, HGF/SF induced angiogenesis in vivo, at pico-molar 
concentrations in the absence o f inflammation in rat corneas HGF/SF and c-met 
mRNA have been isolated from human endothelial and vascular smooth muscle cells 
suggesting autocrine-paracrine interactions Tumour angiogenesis is a prerequisite
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for tumour growth beyond 2-3 mm and for metastasis ' .
Tumour concentrations o f  HGF/SF have been shown to correlate with reduced relapse- 
free and overall survival in patients with primary breast cancer Clinical studies
have shown that a high degree o f neovascularisation is an indicator o f  poor prognosis in 
a wide range o f  human cancers including breast. Several studies have demonstrated 
correlation between indices o f angiogenesis and survival in patients with breast and 
other cancers Tumour proliferation indices also correlate with survival in patients 
with breast cancer The KI-67 index, a measure o f nuclear proliferation, has been 
shown to correlate with tumour grade, oestrogen receptor status, disease-free and 
overall survival in patients with breast cancer 24,231,258,327
The precise biological mechanism activated through deregulated HGF/SF-c-/we^ in 
breast cancer is not known. The aim o f this study therefore, is to determine whether 
HGF/SF levels in primary breast cancer correlate with angiogenesis and tumour cell 
proliferation.
87
Materials and methods 
Patients and assay for HGF/SF
The patient group and ELISA for HGF/SF are described in Chapter 3.
Assessment o f tumour vascularisation /angiogenesis!
Cryostat sections o f  tumour were air dried and fixed in acetone. The avidin biotin- 
peroxidase complex staining procedure was used. Vascular endothelium was detected 
using a monoclonal antibody to CD-34 (QBEnd-10 clone, Serotec, Oxford, UK) used at 
1/250 dilution In a recent report, CD34 was found to be the most strongly
expressed endothelial antigen, staining more vessels reproducibly than CD31 and factor 
VIII Sections were incubated for 1 hour at room temperature and then washed three 
times with TBS. Subsequent reactions were completed using a standard DAKO 
StreptABComplex/HRP duet kit (Dako Ltd., Glostrup, Denmark). The peroxidase 
reaction was developed with diaminobenzidine-hydrogen peroxide and sections 
counterstained with nuclear fast red (Figure 4.1).
Counting o f vessels
Intra-tumoural micro vessel density was determined by a Nikon Labophot-2 microscope 
(Tokyo, Japan) with an ocular graticule (E llA , 19mm, Graticules Ltd., Tonbridge,
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Figure 4.1
Photograph of microvessels detected by anti CD-34 antibody in a frozen section from a 
sample of breast cancer analysed in this study. Magnification: lOOX.
Kent). Microvessel density was assessed in areas o f tumour containing the most dense 
areas o f microvessels identified under low power magnification ^  countable
vessel was defined as any brown-staining endothelial cell or cluster, clearly separate 
from adjacent microvessels, tumour cells or connective tissue element However, the 
use o f cryostat sections limit the spatial resolution o f countable microvessels. Another 
method o f assessing tumour angiogenesis, described by Porschen et a l using 
morphometric methods for cryostat sections, was also used Tumour vascular 
volume was assessed using a point counting method using an eyepiece graticule. This 
method has been used to assess tumour angiogenesis in oesophageal and rectal cancers
227,228
Percentage tumour vascular volume t%TVV)
The percentage tumour vascular volume was assessed using a point counting method 
Sections were examined at 200X magnification and a point was counted if  a cross 
fell onto a vessel and recorded as a coincidence. A minimum o f  1000 points were 
counted per section. The proportion o f tumour occupied by blood vessels was then 
expressed as a ratio o f coincidences/points counted xlOO.
Microvessel densitv (MVDI
Microvessels were counted from areas o f maximum vessel density at 200X  
magnification (0.720 mm^)
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Assessment o f tumour proliferation
The nuclei o f  proliferating cells were stained with the monoclonal antibody KI-67 
which detects a proliferation-associated nuclear antigen Cryostat sections air-dried 
and acetone-fixed were incubated for 1 hour in 1:50 dilution o f  MIB-1, anti-KI-67 
antibody (Immunotech S.A., Marseilles, France) and washed 3 times in TBS. 
Subsequent reactions were completed using a standard DAKO StreptABComplex/HRP 
duet kit (Dako Ltd., Glostrup, Denmark). The peroxidase reaction was developed with 
diaminobenzidine-hydrogen peroxide and sections counterstained with nuclear fast red 
(Figure 4.2). Sections were counted, in tumour areas containing the highest density o f  
stained nuclei, as determined by an initial scan at low magnification Sections were 
assessed at 400X magnification and nuclei scored positive if  any brown staining was 
seen. A minimum o f  1000 nuclei were counted per section. The KI-67 index was then 
expressed as a percentage.
Statistical analysis
The relationships between HGF/SF levels, % T W , MVD and KI-67 index were 
analysed by linear regression analysis. The relationship between these variables, 
clinico-pathological variables, disease-free survival and overall survival was tested by 
Mann-Whitney or Kruskal-Wallis tests.
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Figure 4.2
Photograph of nuclei detected by MIB-1 (KI-67 ) antibody in a frozen section from a sample 
of breast cancer analysed in this study. Magnification: lOOX.
Results (appendix 3)
Patient data
The median follow-up for patients in this study was 61 months (range 7-89 months). 
Local recurrence was observed in 3 patients, local and systemic recurrence in 9 patients 
and systemic recurrence in 16 patients. All patients with systemic recurrence died from 
metastatic disease.
HGF/SF levels in breast cancer
The concentration o f  HGF/SF in breast cancers ranged between 58-1604ng/100mg total 
protein; mean 396ng/100mg total protein. The relationship between HGF/SF, disease- 
free survival, overall survival and clinico-pathological variables are discussed in 
Chapter 3.
Tumour vascularisation
The mean % T W  was 6.3% (median 5.7%, range 2-15%) which is similar to the mean 
% T W  found in rectal and oesophageal cancers by Porschen et a l The mean MVD  
was 81 (median 76, range 28-229) and is similar to those reported in other studies. 
There was a significant correlation between %TVV and MVD, r=0.648, p<0.001 
(Figure 4.3). Tumour levels o f  HGF/SF demonstrated a significant positive linear
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Figure 4.3
Scatterplot showing relationship between tumour microvessel density (MVD) and percentage 
tumour vascular volume (%T W ).
relationship with %TVV: r=0.493, p<0.001, (Figure 4.4) and MVD: r=0.279, p<0.02, 
(Figure 4.5, Table 4.1). In addition, % T W  correlated significantly with reduced 
disease-free survival, p<0.04, (Table 4.1). There were no significant correlations 
between %TVV or MVD, overall survival and clinico-pathological prognostic variables 
(Table 4.1 and 4.2).
Tumour proliferation
The mean KI-67 index was 19.9% (median 19%, range 4-59%). There was a significant 
positive linear correlation between HGF/SF levels and KI-67 index: r=0.255, p<0.04, 
(Figure 4.6). KI-67 index correlated significantly with overall survival, p<0.05, (Table 
4.3). There was a non-significant trend between histological grade and KI-67 index. 
However, when KI-67 index in well differentiated breast cancers (grade 1, median 12.0) 
was compared to moderate-poorly differentiated cancers (grades 2 and 3, median 20.0) 
this trend reached significance, p<0.02, Mann-Whitney. There were no significant 
correlation between KI-67 index, % T W , disease-free survival and clinico-pathological 
prognostic variables (Table 4.3).
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Figure 4,4
Scatterplot showing relationship between percentage tumour vascular volume 
(%TVV) and HGF/SF levels in breast cancer patients.
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Figure 4.5
Scatterplot demonstrating relationship between microvessel density (MVD) to HGF/SF levels in 
human breast cancer patients.
Table 4.1
Univariate analysis o f  the relationship between % tumour vascular volume (%TVV) to 
prognostic variables. The relationship between HGF/SF and tumour size to % T W  was 
tested by linear regression analysis. The relationship between disease-free survival, 
overall survival, nodal status, tumour grade, oestrogen receptor and vascular invasion to 
%TVV was tested by Mann-Whitney test. The relationship between tumour grade and 
%TVV was tested by Kruskal-Wallis test.
Parameter n Correlation to 
%TVV
p value
HGF/SF 71 R=0.493 <0.001*
Tumour size 72 R=0.197 0.1
Parameter Values n Median
%TVV
p value
Disease-free Relapse 27 6.5 0.04*
survival Disease-free 45 5.3
Overall Survival Dead 24 6.4 0.21
Alive 48 5.35
Nodal status Positive 34 5.85 0.19
Negative 37 5.1
Histological grade 1 12 5.05 0.34
2 31 5.8
3 26 5.7
Oestrogen Positive 29 5.1 0.66
receptor Negative 31 5.6
Lymphatic Positive 21 6.1 0.6
invasion Negative 51 5,3
* statistical y significant
% T W  not available in one patient. HGF/SF levels not available in 2 patients. 
Lymph node status unknown in 4 patients.
Tumours not graded in 7 patients.
Oestrogen receptor status unknown in 12 patients.
Table 4.2
Univariate analysis o f  the relationship between tumour microvessel density (MVD) to 
prognostic variables. The relationship between HGF/SF and tumour size to MVD was 
tested by linear regression analysis. The relationship between disease-free survival, 
overall survival, nodal status, oestrogen receptor and vascular invasion to MVD was 
tested by Mann-Whitney test. The relationship between tumour grade and MVD was 
tested by Kinskal-Wallis test.
Parameter n Correlation to 
MVD
p value
HGF/SF 71 0.279 0.019*
Tumour size 72 0.147 0.217
Parameter Values n Median MVD p value
Disease-free Relapse 27 83.0 0.11
survival Disease-free 45 69.0
Overall Survival Dead 24 82.0 0.48
Alive 28 74.5
Nodal status Positive 33 82.0 0.45
Negative 36 74.0
Histological grade 1 8 55.0 0.244
2 31 84.0
3 26 78.5
Oestrogen Positive 30 74.0 0.92
receptor Negative 31 72.0
Lymphatic Positive 21 83.0 0.68
invasion Negative 51 75.0
* statistical ly significant
% TVV not available in one patient. HGF/SF levels not available in 2 patients. 
Lymph node status unknown in 4 patients.
Tumours not graded in 7 patients.
Oestrogen receptor status unknown in 12 patients.
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Figure 4.6
Scatterplot demonstrating relationship between KI-67 index and HGF/SF levels 
in breast cancer patients.
Table 4.3
Univariate analysis o f the relationship between KI-67 index and prognostic variables. The 
relationship between HGF/SF, %TVV and tumour size to KI-67 was tested by linear 
regression analysis. The relationship between disease-free survival, overall survival, 
nodal status, oestrogen receptor and vascular invasion to KI-67 was tested by Mann- 
Whitney test. The relationship between tumour grade and KI-67 was tested by Kruskal- 
Wallis test.
Parameter n Correlation to KI-67 p value
HGF/SF 71 0.255 <0.04*
% T W 72 0.288 0.56
Tumour size 72 -0.022 0,97
Parameter Values n Median KI-67 p value
Disease-free Relapse 28 21.5 0.15
survival Disease-free 44 16.5
Overall Survival Dead 24 25.0 0.046*
Alive 48 16.5
Nodal status Positive 35 19.0 0.87
Negative 37 20.0
Histological grade 1 8 10.9 0.081
2 31 22.0
3 26 19.25
Oestrogen Positive 30 16.5 0.19
receptor Negative 31 19.0
Lymphatic Positive 21 20.0 0.47
invasion Negative 50 19.0
* statistically significant
% TVV not available in one patient. HGF/SF levels not available in 2 patients. 
Lymph node status unknown in 4 patients.
Tumours not graded in 7 patients.
Oestrogen receptor status unknown in 12 patients.
Discussion
Tumour proliferation and angiogenesis are important prognostic variables in breast 
cancer. Many o f these functions are controlled by growth factors through their receptors 
via autocrine or paracrine loops. However, the intrinsic and extrinsic factors that control 
these variables are the subject o f ongoing investigation. Tumour growth and metastasis 
are dependent on angiogenesis Studies have demonstrated a significant relationship 
between angiogenesis and metastasis in patients with breast cancer The
development o f angiogenesis requires a complex cascade o f events controlled by 
soluble or tissue-bound factors Factors such as VEGF and basic FGF are thought to 
play an important part in breast cancer angiogenesis and growth VEGF,
produced by normal and malignant epithelial cells, is a paracrine mediator o f  
endothelial cell growth binding to receptors Flt-1 (VEGF receptor-1) and KDR (VEGF 
receptor-2) Several studies have found an association between VEGF expression 
and relapse-free and overall survival, with significant shorter survival times in VEGF- 
rich tumours In addition factors such as basic FGF, TGF-a, TGF-p and EGF 
receptor expression has been shown to correlate with microvessel density in human 
breast cancer In particular TGF-a/EGF-receptor paracrine and TGFp/TGFp-receptor 
autocrine endothelial loops correlate significantly with tumour microvessel density
HGF/SF has been shown to possess potent angiogenic properties both in vitro and in 
vivo. Both large vessel and microvessel endothelial cells express the c-met receptor and 
are biologically responsive to HGF/SF 25,94,192,243.245,249 p ^ s  been shown to
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promote proliferation, motility, invasion and capillary morphogenesis of endothelial 
cells in vitro. In addition to producing HGF/SF, vascular smooth muscle cells express c- 
met receptor and are responsive to HGF/SF 4^,126,129,249 studies suggest that
HGF/SF may interact with other cytokines, such as TNF-a and IL-1 in promoting 
tumour invasion and angiogenesis HGF/SF has been shown to stimulate 
angiogenesis in vivo using the mouse matrigel assay and a rat cornea assay 4^^ 192 po^p 
reports, HGF/SF induced angiogenesis in a dose-dependent fashion with a maximal 
response similar in intensity to those induced by basic FGF or VEGF. Histological 
analysis o f the assays excluded the possibility of HGF/SF stimulating angiogenesis 
through inflammation.
This study has demonstrated a correlation between tumour levels o f HGF/SF and 
indices of tumour neovascularisation suggesting that HGF/SF may be linked to tumour 
angiogenesis in breast cancer. This observation has been subsequently confirmed 
HGF/SF levels have been shown to be significantly associated with tumour levels of 
von Willebrand's factor (vWF), an endothelial-specific marker protein, in patients with 
breast cancer Transfection o f HGF/SF into the human breast cancer cell line MDA- 
MB-231 results in tumours growing more rapidly than non-transfected cells when 
implanted into mammary pads o f nude mice . The proliferation rates in vitro of 
HGF/SF transfected MDA-MB-231 breast cancer cells however was no greater than in 
non-transfected cells. Histological analysis of the tumours produced by HGF/SF 
transfected cells demonstrated significantly higher microvessel densities when 
compared to tumours derived from non-transfected cells. Increased tumour growth rate
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in this model appeared to be due, in part, to an angiogenic response induced by 
HGF/SF. Laterra et a l observed higher growth rates and microvessel densities in 
HGF/SF transfected 9L rat glioma cells implanted into rats when compared to non- 
transfected tumour cells . Similar observations have also been reported in HGF/SF 
transfected human glioblastoma cells grown in immunocompromised mice These 
studies confirm the observations o f  the present study and further support the hypothesis 
o f linking HGF/SF and tumour angiogenesis. In contrast, in a series o f  135 primary 
breast cancers Toi et a l were unable to demonstrate a correlation between HGF/SF, 
VEGF or basic FGF levels with tumour microvascular density Thus, further studies 
are necessary to confirm the observed correlation between HGF/SF and tumour 
angiogenesis in human breast cancer. This is important because angiogenesis is an early 
event in tumour development and is essential for tumour growth, metastasis and 
survival o f metastatic deposits. Truncated peptide fragments o f  the a-chain o f HGF/SF, 
designated HGF/SF NK-1 and NK-2, have been shown to antagonise HGF/SF-mediated 
angiogenesis These and other HGF/SF antagonists may provide new therapeutic 
strategies for the treatment o f breast cancer.
Proliferation is an important prognostic variable in breast cancer. Many studies have 
shown that a high number o f mitotic figures, high KI-67 index, high tritiated thymidine 
or bromodeoxyuridine labeling indices and a high percentage S-phase are associated 
with poor prognosis in breast cancer The KI-67 index has been shown to correlate 
with tumour grade, oestrogen receptor status and overall survival in breast cancer 
24,113,231,258,327 sij^iJady, iu this study KI-67 index correlated reduced overall survival in
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patients with breast cancer. Tumour cell proliferation may be controlled by various 
growth factors interacting via autocrine or paracrine loops. A  number o f  growth factors 
and their receptors have been shown both in vitro and in vivo  to relate to tumour cell 
proliferation in breast cancer. The type 1 family o f growth factor receptors, which 
include EGF receptor and c-erbB-2 are expressed in both normal breast ductal 
epithelium and in some breast cancers Growth o f  normal human mammary epithelial 
cells is dependent on the synergistic interaction between EGF and IGF-1 when grown in 
serum-free conditions The receptor to EGF and its physiological ligands EGF and 
TGF-a are overexpressed in aroimd 50% o f primary human breast cancers High 
levels o f EGF receptor have been shown to correlate with poor prognosis and failure to 
respond to hormone therapy in breast cancer in vitro, autocrine growth
dependence on the TGF-a/EGF-receptor system has been observed in the MDA MB- 
468 breast cancer cell line Increased EGF receptor expression has been shown to 
correlate with indices o f  tumour proliferation in patients with breast cancer 
Furthermore, De Jong et a l observed that the combined expression o f  TGF-a/EGF- 
receptor demonstrated a stronger correlation to mitotic activity than EGF receptor 
expression alone The epithelial tyrosine kinase receptor encoded by c-erbB-2 is 
overexpressed at very high levels in about 20% o f breast cancers and is indicative o f  
poor prognosis The heregulins are a family o f  growth factors that activate erbB-2 
when present as a heterodimer with erbB-3, EGF receptor and erbB-4 and have been 
shown to support growth o f human mammary epithelial cells in serum-free conditions 
in the absence o f  EGF and IGF-1 Studies in vitro demonstrate that constitutive
autocrine activation o f c-erbB-2 receptor in MCF-7 breast cancer cells transfected with
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heregulin results in enhanced proliferation In addition, c-erbB-2 overexpression in 
human breast epithelial cells has been shown to confer growth factor independence 
Tumour proliferation indices in vivo have been shown to correlate with c-erbB-2 
expression in human breast cancers TGF-p is the most potent known inhibitor o f  the 
progression o f normal mammary epithelial cells through the cell cycle It is 
expressed in both normal mammary epithelium and stromal cells and may be involved 
in both autocrine and paracrine growth inhibition Although most breast cancer
cell lines are growth inhibited by TGF-P, there is little evidence that this occurs in vivo 
50,302 Auvinen et a l found a negative correlation between the S-phase fraction
and TGF-p However, Dublin et a l found no correlation between these variables in 
breast cancer and similarly, D e Jong et a l failed to demonstrate any relationship 
between TGF-p expression and mitotic activity Paradoxically, increased
expression o f TGF-P has also been found to correlate with poor prognostic features in 
breast cancer Thus in breast cancer the negative autocrine effect o f  TGF-p on breast 
epithelial cells may be lost, although the clinical significance o f these observations is as 
yet uncertain,
In vitro studies have shown that HGF/SF induces growth in a variety o f benign and 
malignant epithelial cell types including breast The results o f this study suggest a 
link between HGF/SF levels and tumour proliferation in vivo. However, this 
observation has not been confirmed. Animal experiments have shown that the rate o f  
tumour cell proliferation is inversely proportional to the tumour microvessel distance 
Tumour vascularisation may therefore influence tumour cell proliferation and in the
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present study there was a non-significant trend between tumour vascular volume and 
KI-67 index (p=0.056). Lamszus et a l reported that enhanced tumour proliferation 
induced by HGF/SF in breast cancer cells was a function o f angiogenesis rather than 
direct stimulation o f cell growth . In support o f this observation suppression o f  VEGF 
induced angiogenesis has been shown to suppress tumour growth in vivo
In conclusion, this study demonstrates a significant correlation between HGF/SF levels, 
% tumour vascular volume (TVV), microvessel density (MVD) and KI-67 index. These 
results provide further supportive evidence that HGF/SF may be linked to the 
mechanisms o f tumour progression.
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Chapter 5 : Conclusions
HGF/SF-c-/we/ is involved in stromal-epithelial regulation o f cellular processes such as 
growth, dissociation, motility and invasiveness When coordinated they appear to 
play an important role in morphogenesis o f  epithelial tissues There is increasing 
evidence that HGF/SF-c-me/ is an essential regulating component o f breast duct 
development 3^,208,276,334 ^he results o f this thesis support the hypothesis that aberrant 
HGF/SF-c-we/ expression occurs in human breast cancer and is related to disease 
progression.
Investigation on frequencv o f loss o f heterozvgositv o f the c-met proto-oncogene in 
human breast cancer
Aberrant HGF/SF-c-we/ function in breast cancer was first suggested by the observation 
of a high frequency o f  LOH at 7q31, the c-met locus, in human breast cancer patients 
Furthermore, LOH o f this gene was related to a significant reduction in both disease- 
free and overall survival. This finding suggested the presence o f  an important tumour 
suppressor gene at 7q31, possibly c-met, in human breast cancer. In our series o f  111 
patients with primary breast cancer, 52 were heterozygous and LOH at 7q31 was 
observed in only 4% o f these cases. The presence o f a tumour suppressor gene at 7q31 
is controversial and the identity o f this putative gene is unknown. In human breast 
cancer the reported frequency o f LOH at this locus ranges between 4-83%. However, in 
a series o f  683 breast cancers, Devilee et a l observed LOH at 7q31 in 19% o f  cases with
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no prognostic significance Furthermore, a recent study by Bieche's group observed 
LOH at 7q31 in 20% o f  breast cancers The wide range o f  frequencies o f  LOH at 
7q31 may be due to a fragile site, FRA7G, located at 7q31.1 Loss o f  heterozygosity 
may therefore be the result o f  intrinsic chromosome instability rather than the presence 
o f  a tumour suppressor gene. The identity o f  any putative tumour suppressor gene on 7q 
remains unknown. Microsatellite studies o f  7q31.1 have identified several areas o f  
frequent deletion, (D7S522, D7S480, D7S486 and D7S480-D7S650), which do not 
include the c-met locus p^rthermore, the biological properties o f  c-met are
clearly those o f  a proto-oncogene.
HGF/SF-c-met ligand receptor svstem in human breast cancer
The work presented in this thesis has demonstrated a statistical association between 
HGF/SF and c-met in relation to disease-relapse in patients with primary breast cancer. 
This observation provides strong support to the hypothesis that aberrant HGF/SF-c-mer 
expression occurs in breast cancer. Furthermore, the data confinn the presence o f  
increased HGF/SF levels in human breast cancer when compared to tumour-free breast 
tissue. HGF/SF levels demonstrated significant associations with disease-relapse and 
death. However, HGF/SF levels did not correlate with other clinico-pathological 
variables. These findings are concordant with three similar studies 331,332,335 
protein was observed in all samples o f  tumour-free breast tissue and in a proportion o f  
patients with breast cancer. Patients with detectable c-met demonstrated a significant 
association with disease-relapse. This pattern o f receptor expression and relationship to
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disease progression has subsequently been confirmed
Although HGF/SF-c-7we/ appears to be an important paracrine regulator o f  breast duct 
development, several in-situ hybridisation studies have detected HGF/SF mRNA in 
both benign and malignant breast epithelial cells 3^,126,208,276,307,317,334 observation 
suggests that both autocrine and paracrine signalling are possible with HGF/SF-c-wer. 
Autocrine HGF/SF-c-me/ activation has been shown to induce tumorigenesis, invasion 
and metastasis in breast epithelial cells both in vitro and in vivo HGF/SV-c-met
expression is regulated both systemically and locally. Oestrogen and progesterone are 
able to upregulate both HGF/SF and c-met expression At the cellular level, breast 
epithelial cells regulate fibroblast production o f HGF/SF through SF-IF (positive) and 
TGF-p (negative) pathways 4^6,267,268 levels o f  HGF/SF also down-regulate c-
met expression It is possible that in the majority o f  breast cancers increased HGF/SF 
levels down-regulate c-met expression through autocrine or paracrine signalling. Failure 
o f  regulatory mechanisms may allow inappropriate c-met expression with uncontrolled 
growth, dissociation, invasion and ultimately metastasis. This failure may involve the 
formation o f an HGF/SF-c-mer autocrine loop.
HGF/SF. angiogenesis and tumour cell proliferation in primary breast cancer
A significant correlation between HGF/SF levels and tumour angiogenesis was 
observed in patients with breast cancer. HGF/SF has been shown to promote 
angiogenesis both in vitro  and in vivo and formation o f a HGF/SF-c-me/ autocrine loop
101
in breast cancer cells w ill promote tumour angiogenesis in mice 4^?>248 studies
have confirmed that HGF/SF promotes tumour angiogenesis in other tumour types in 
vivo  4^9.150 evidence o f  a link between HGF/SF and tumour angiogenesis is
provided by the observation o f  a direct relationship between HGF/SF and von 
Willebrand's factor in breast cancer However, in a study o f  135 patients with breast 
cancer. Toi et a l failed to demonstrate any relationship between HGF/SF and tumour 
microvessel density In this study, HGF/SF levels significantly correlated with the 
KI-67 index and therefore with tumour proliferation. HGF/SF is known to promote 
breast epithehal cell growth in vitro 11 *^208,252 ^Q^gygp HGF/SF promotion o f breast 
cancer in vivo appears to be related to angiogenesis rather than direct stimulation o f  
cellular proliferation The observations o f the present study regarding HGF/SF and 
tumour proliferation in breast cancer thus remain unconfirmed.
HGF/SF as a possible target in cancer treatment
The metastatic spread o f tumours is the most important factor in determining survival in 
breast cancer patients. The current knowledge o f  the effects o f  HGF/SF mediated by c- 
met on tumour cells both in vitro and in vivo imply that it may play a role in tumour 
dissemination in vivo, HGF/SF thus presents a possible target for anti-tumour therapy. 
Several factors are known to inhibit the action o f  HGF/SF. Gamma-linolenic acid 
(GLA) has been shown to be cytotoxic toward cancers both in vitro and in vivo 
GLA has been shown to inhibit HGF/SF stimulated tumour cell motility, invasion and 
membrane ruffling at non-toxic cellular concentrations possibly through the regulation
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o f  E-cadherin ^^ *^^ 20,121 ^  naturally occurring HGF/SF antagonist that specifically 
inhibits HGF/SF induced mitogenesis has been identified This antagonist is an 
alternative HGF/SF transcript that may compete with binding to the c-met receptor. The 
N-terminal hairpin domain truncated transcripts also possess antagonistic behavior. 
HGF/SF NK-1 and NK-2 are naturally occurring antagonists o f  HGF/SF-induced matrix 
degradation However, HGF/SF NK-1, NK-2 and NK-3 all stimulate motility 
HGF/SF NK-4 completely inhibits HGF/SF-stimulated mitogenic, motogenic and 
morphogenic activities Furthermore, NK-4 possesses no other biological activity and 
may be a candidate for future therapeutic investigation. HGF/SF-induced tumour cell 
motility and invasion are also inhibited by both interleukins 4 and 12 ^^ 3,io6,308 HGF/SF 
induced cancer cell invasion can be inhibited by increasing E-cadherin expression 
120,121 E-cadherin cell-cell adhesion by Tiam 1 or RacV12 reduces HGF/SF
induced cell dissociation Thus several mechanisms have been identified in vitro that 
may form the basis o f  direct cellular antagonism o f  the effects o f HGF/SF on tumour in 
vivo.
HGF/SF action may be inhibited through action on pro-HGF/SF cleavage mechanisms. 
In response to tissue injury, HGF activator (HGFA) is activated and cleaves pro- 
HGF/SF. Two inhibitors o f HGFA have recently been identified and are produced by 
the MKN45 gastric carcinoma cell line ^^^’^ 22 R^gg^Htion o f HGFA expression through 
HGFA inhibitors may represent another pathway o f modulating HGF/SF effects in 
tumour.
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In conclusion, HGF/SF-c-we/ activity in tumour may play an important role in disease 
progression. Inhibition o f this interaction by agents such as GLA, HGF/SF NK-4 or 
interleukins 4 and 12 may provide new anti-metastatic treatment. However, the effects 
o f these inhibitors have only been studied in vitro. Further investigations are necessary 
on the effects, efficacy and safety o f these antagonists in vivo.
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Appendix 1
Clinicopathological variables, disease-free, overall survival, c~met expression and 
HGF/SF levels in 73 patients w^ ith breast cancer.
Patient
Number
Size
(mm)
Grade Nodes RFS
(months)
OS
(months)
HGF/SF£ R LI
478 677
248 440
474 40 13249
275 729
379 148
633 915
437 465
505 530
529 25 427
512 513
503 20 36 621
400 63 350
296 50 59530
213 40
300 441
145 40 252
272 25 30 603
446 330
475 160429
293 60 163
425 99534
292 25
261 20 552
377 491
373 48 1045
220 60 NOiss 32034 >60
>60522 79830
531 46249 >60
372 Medullary 420>60 >60
289 Mucoid >60 255>60
310 20 184>60 >60
547 135>60 >60
511 60 >60 393>60
256 331>60>60
>60206 Lobular >60
168294 25 >60>60
578 297>60 >60
489 >60 >60
120455 NDISS >6063 >60
257 23149 >60 >60
>60560 310>60
832165 >60>60
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Patient
Number
Age
(years)
Size
(mm)
Grade Nodes ER LI RFS
(months)
OS
(months)
c-met HGF/SF
330 55 25 2 N P N >60 >60 N 100
407 54 30 Lobular NDIss N N >60 >60 N 243
477 66 40 3 P P N >60 >60 N 396
561 71 25 3 P ? P >60 >60 N 60
396 62 30 3 N N N >60 >60 N 406
319 65 30 Lobular N N N >60 >60 N 374
217 42 40 3 N N N >60 >60 N 60
383 65 20 2 N P P >60 >60 N 324
260 78 50 2 N P N >60 >60 N 315
451 73 10 3 N N N >60 >60 N 129
374 50 25 3 N P P >60 >60 N 911
154 36 20 3 N ? N >60 >60 N 62.4
516 63 20 2 N P N >60 >60 N 383
515 45 25 2 NDIss P N >60 >60 N 456
96 74 20 1 N P N >60 >60 N 66
494 64 40 3 P ? N >60 >60 N 319
313 39 28 2 N N N >60 >60 N 233
517 64 20 2 P p N >60 >60 N 345
334 54 30 3 P N P >60 >60 N 370
171 35 20 2 P P N >60 >60 N 95
241 62 10 1 N P N >60 >60 N 152
410 36 60 3 N P P >60 >60 N 620
462 43 20 Lobular P P N >60 >60 N 84
442 50 20 2 N N N >60 >60 N 475
436 62 5 1 N N N >60 >60 N 185
306 42 40 1 p N N >60 >60 N 84
433 72 20 1 P P N >60 >60 N 473
137 46 55 Mucoid N N N >60 >60 N 510
417 40 15 3 P N N >60 >60 N 588
565 64 30 2 N ? N >60 >60 N 279
151 68 20 2 N P P >60 >60 N 558
Key
N negative
P positive
NDiss not dissected
ER oestrogen receptor status
LI lymphatic invasion
RFS relapse-free survival
OS overall survival
HGF/SF ng/lOOmg total protein.
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C-met and HGF/SF levels in tumour-ffee breast tissue.
Patient
number
C-met HGF/SF
561N P 90
533N p 88
RM p 213
319N P 101
560N P 114
213N P 170
424N P 100
063N P 162
151N P 66
522N P 200
Key
RM reduction maminoplasty
P positive
HGF/SF ng/lOOmg total protein.
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Appendix 2
Multivariate Analyses (performed by Dr. I C. McKay, University Dept. Pathology, Western 
Infirmary, Glasgow)
1. Multiple linear regression
The following were used as potential prognostic indicators to relapse-fi'ee survival (RFS) and overall 
survival;
• HGF in tumoui- / ng per lOOmg protein
• MET in tumour
• Diameter of tumour / mm
• Age / yrs
• Métastasés in lymph nodes
• Oestrogen receptors (ER)
• Invasion of lymphatics (LI)
Histological grade
By stepwise removal of non-significant factors fi"om the model, we were left with the following 
variables in our regression equation:
Variable Coefficient SE of coeff T P
HGF -0.032512 0.008833 -3.681 0.0006
MET -12.841323 5.553414 -2.312 0.0254
Nodes -13.142986 5.303057 -2.478 0.0170
ER 11.448547 5.226806 2.190 0.0337
(Constant) 63.017702 5.771831 10.918 0.0000
Thus, in addition to the variables already found to be of probable prognostic value, it seems that the 
presence of oestrogen receptors, when considered along with other factors, may be of some 
prognostic value. To allow for the interaction (both biochemical and statistical) between HGF and 
MET, a non-linear regression model was used in which the product MET x HGF is introduced, in 
this model the predicted value of RFS is calculated fi'om a formula of the form
RFS = (ax MET x HGF )+(b x ER)+(c x nodes) + (d x HGF) + (e x MET) + k ,
where MET, HGF, ER, nodes are all coded 0 for negative and I for positive, and the HGF is 
measured in ng per lOOmg protein. The parameters a, b, c, d, k were all adjusted to make the 
prediction as accurate as possible, as judged by the sum of the squares of the errors in predicted RFS. 
In this model it was found that the term containing MET by itself (without HGF) became statistically 
non-significant, the effect of MET being entirely attributable to its interaction with HGF. After 
removing MET from the model and adjusting &e coefficients to give the best predictions, the 
optimised coefficients were found to have the following values.
Parameter Estimate Asymptomatic Std. error Asymptomatic 95% Confidence Interval
Lower Upper
a -0.027523651 0.010252666 -0.048106736 -0.006940565
b 9.867950158 4.650936421 0.530805683 19.205094634
c -14.77398629 4.671878632 -24.15317401 -5.394798574
d -0.027909886 0.008227353 -0.044426987 -0.011392786
k 63.452290577 5.072409907 53.269002771 73.636678382
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The extent to which this model could predict RFS is illustrated in the following graph.
>60
§50
2 40
Predicted relapse*free survival / months
2. Linear discriminant analysis
This technique consists of calculating a linear function (the 'discriminant function') of the potential 
prognostic indicators and optimising it until it gives the best prediction o f which patients will have 5 
years or more recurrence-free survival, and which patients will not. In the process, the prognostic 
indicators are tested to see if they are making a statistically significant contribution to the accuracy o f the 
prognosis, and those that are not ar e removed from the model.
Technical details;
Method: Wilks' lambda
Criteria: F value for entry of a factor: 3.84
F values for removal o f a factor: 2.71
Prior probabilities computed from group sizes.
Missing values replaced with mean values.
Discriminant function based on the within-groups covariance matrix.
Initially the following variables were considered for inclusion in the model:
AGE, SIZE, GRADE, NODES, ER, LI, MET, HGF
Only three prognostic indicators satisfied the criterion for inclusion in the model, and none thereafter 
satisfied the criterion for removal from the model. These indicators that appeared to contribute 
significantly to the prognosis were as follows.
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Variable added 
Step to the model
1 MET
2 HGF
3 NODES
Wilks’
Lambda
.11951
.61652
.53069
P
value
.0006
.0000
.0000
Label
MET in tumour
HGF in tumour / ng per lOOmg protein 
Métastasés in lymph nodes
After these variables had been included in the model the next most significant was the size of the 
tumour/mm but the significance was not nearly high enough to justify its inclusion (P =0.317).
Unstandardised canonical discriminant function coefficients
NODES
MET
HGF
(Constant)
1.1896617 
1.6425366 
2.59976921 E-03 
-2.3451422
Thus, the recipe for prediction is as follows; calculate a score by multiplying the HGF level (in ng per 
lOOmg protein) by 2.6 x 10'^ ; add 1.19 if there are métastasés in the nodes; add 1.64 if the tumour is MET 
positive. Subtract 2.345 and call the answer your discriminant function. If the answer is less than 0.2 you 
predict 5 years of recurrence-free survival. The distribution of the patients over the range of values of this 
discriminant function is shown on the following rough histograms. It can be seen that there is a fair 
overlap between the two groups (recurrence and no recurrence).
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Classification o f results:
No. of cases Predicted group membership
Actual group Recurrence No recurrence
Recurrence 28 20 (71.4%) 8 (28.6%)
No recurrence 45 8 (17.8%) 37 (82.2%)
Percent of "grouped" cases correctly classified: 78.08%.
Alternatively, the discriminant function can be used to estimate the probability of recurrence-free survival 
as follows:
0.8
£  0.6 
E
S 0.4 -
to
Discriminant function
Probability of 5 years' recurrence-free survival for various values of the linear discriminant function.
3. Non-linear discriminant analysis
This was carried out using the same criteria as in the linear discriminant analysis, but included among the 
prognostic indicators was the product obtained by multiplying two of them together, namely MET x 
HGF.
The technique consists of calculating an algebraic function (the 'discriminant function') of the potential 
prognostic indicators and optimising it until it gives the best prediction o f which patients will have 5 
years or more recurrence-free survival, and which patients will not. In the process, the prognostic 
indicators are tested to see if they are making a statistically significant contribution to the accuracy o f the 
prognosis, and those that are not are removed from the model.
Method: Wilks' lambda
Criteria: F value for entry o f a factor: 3.84
F values for removal of a factor: 2.71
Prior probabilities computed from group sizes.
Missing values replaced with mean values.
Discriminant function based on the within-groups covariance matrix.
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Initially the following variables were considered for inclusion in the model:
AGE, SIZE, GRADE, NODES, ER, LI, MET, HGF, MET x HGF
In this analysis one o f the interesting findings was that the effect of MET by itself (independent of HGF) 
became statistically non-significant; i.e. there was no evidence that MET had any other effect than to alter 
the prognostic weight that needed to be given to the HGF assay. It had no apparent influence independent 
of HGF. The other interesting aspect of this model was that it gave more accurate prognoses than the 
linear model, despite the fact that the discriminant function still contained only three significant terms.
Only three prognostic indicators satisfied the criterion for inclusion in the model, and none thereafter 
satisfied the criterion for removal from the model. These indicators that appeared to contribute 
significantly to the prognosis were as follows.
Variable added Wilks' P
Step to the model Lambda value Label
1 MET X HGF .72341 .0001
2 NODES .61155 .0000 Métastasés in lymph nodes
3 HGF .51920 .0000 HGF in tumour / ng per lOOmg protein
After these variables had been included in the model the next most significant was the size of the 
tumour/mm but the significance was not nearly high enough to justify its inclusion (p =0.386).
Unstandardized canonical discriminant function coefficients
NODES 1.3166844
HGF 2.05971933E-03
MET X HGF 3.37683212E-03
(Constant) -2.1241668
Thus, the recipe for prediction is as follows: calculate a score by multiplying the HGF level (in ng of 
HGF per lOOmg of tumour protein) by 0.00206 if the tumour is MET negative, or by 0.00544 if the 
tumour is MET positive; add 1.32 if there are métastasés in the nodes. Subtract 2.124 and call the answer 
your discriminant fimction. If the answer is less than 0.263 you predict 5 years o f recurrence-free 
survival.
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The distribution of the patients over the range of values of this discriminant function is shown on the 
following rough histograms. It can be seen that there is fair overlap between the two groups (recurrence 
and no recurrence).
Symbols used in plots:
0 recuiTence within 5 years 1 5 years' recurrence-free survival.
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Classification of results:
No. o f cases Predicted group membership
Actual group Recurrence No recurrence
Recurrence 28 16 (57.1%) 12 (42.9%)
No recurrence 45 2 (4.4%) 43 (95.6%)
Percent of "grouped" cases correctly classified: 80.82%
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An alternative to the prognosis is to use the value of the discriminant function to estimate the 
probability of 5 years' recurrence-free survival using the following graph.
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Discriminant function
4. Analysis of variance and covariance
In this technique, as with the linear regression analysis, an attempt is made to predict the recurrence- 
free survival from the available prognostic indicators, but the continuously-variable factors like age, 
size/mm, HGF level (the covariates) are treated differently from the discretely-valued factors, 
namely grade, nodes, ER, LI, MET. Each factor is tested for the statistical significance of its 
relationship with the 'dependent variable', namely recurrence-free survival.
In the first model used, all the above factors were included. This was done using the Minitab 
command
mtb> glmc9=c2c4 c5 c6 c7 c8 c l l  c l2; 
subc> cova c2 c4 cl2.
The result indicated that the predictive value of most of the factors were not statistically significant, 
as seen by the P values in the analysis of variance table below.
Analysis of Variance for recurrence-free survival
Source DF SeqSS AdjSS AdjMS F P
Age 1 47,2 197.7 197.7 0.60 0.444
Size/mm 1 3545.5 1082.5 1082.5 3.28 0.078
Grade 1267.1 145.5 72.7 0.22 0.803
Nodes 1 2027.0 1136.9 1136.9 3.44 0.071
ER 1 449.9 835.2 835.2 2.53 0.119
LI 1 114.9 0.1 0.1 0.00 0.989
MET I 1751.5 1500.6 1500.6 4.54 0.039
HGF 1 2758.8 2758.8 2758.8 8.35 0.006
Error 41 13538.3 13538.3 330.2
Total 50 25500.2
The clearly insignificant terms were then sequentially removed from the statistical model, and first-
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order interaction terms were introduced, wherever this was found to be justifiable as judged by a 
significant reduction in the residual sum of squares. On introduction of the MET*HGF interaction 
term, MET by itself became insignificant, but it was retained in order to keep the model hierarchical. 
This gave the following results.
Analysis of Variance for recurrence-free survival
Source DF Seq SS AdjSS AdjMS F P
Size/mm 1 2550.9 1500.5 1500.5 4.52 0.037
MET 1 1730.8 533.3 533.3 1.61 0.210
HGF 1 4548.3 6724.7 6724.7 20.24 0.000
MET*HGF 1 2155.3 2271.0 2271.0 6.84 0.011
Nodes 1 1277.6 1277.6 1277,6 3.85 0.054
Error 63 20930.2 20930.2 332.2
Total 68 33193.0
It can be seen that the factors found to be of most significance as predictors of RFS were HGF and 
the interaction between HGF and MET, When the interaction term was included in the model, MET 
by itself did not have a statistically significant effect. In other words, the effects of MET could be 
modeled adequately by the hypothesis that it simply increased the influence of HGF, but did not 
have any other influence of its own.
The presence of métastasés in the nodes, and the size of the tumour in mm, were o f marginal 
significance, and a closer study was made o f their prognostic value, given that MET and HGF 
effects were already being considered. The removal of either size or nodes fi'om the statistical model 
tended to make the other more significant. The most likely explanation for this is that the 
information contained in them overlaps substantially. In other words, the size of the tumour may be 
of prognostic value mainly because it is associated with a greater risk of métastasés, and this greater 
risk is also reflected in the lymph node involvement The effect of removing either nodes or size firom 
the prognostic model is illustrated below.
Analysis of Variance for recurrence-free survival with nodes excluded
Source DF Seq SS AdjSS AdjMS F P
MET 1 2100.9 308.9 308.9 0.94 0.337
HGF 1 4959.3 6853.8 6853.8 20.77 0.000
MET*HGF 1 2004.2 2141.2 2141.2 6.49 0.013
Size/mm 1 2557.1 2557.1 2557.1 7.75 0.007
Error 68 22440.7 22440.7 330.0
Total 72 34062.2
Analysis o f Variance for recurrence-fi'ee survival with size excluded
Source DF SeqSS AdjSS AdjMS F P
MET 1 1674.0 581.2 581.2 1,66 0.202
HGF 1 4846.6 6911.3 6911.3 19.72 0.000
MET»HGF 1 2083.3 2244.9 2244.9 6.41 0.014
Nodes 1 2158.2 2158.2 2158.2 6.16 0.016
En'or 64 22430.7 22430.7 350.5
Total 68 33193.0
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Conclusions
The analysis o f variance and the discriminant analysis lead to much the same conclusions.
1. The prognostic factors that were found to contribute significantly to the prediction o f  relapse-free 
survival were HGF and MET, In some statistical models there was also a strong indication that the 
presence of métastasés in the lymph nodes, and the size o f the tumour (diameter in mm) was o f  
prognostic significance. In only one model was there any indication that the presence o f estrogen 
receptors might be o f some prognostic significance.
2. There was no evidence in any o f  our analyses that the age o f the patient, the histological grade o f the 
tumour or invasion o f the lymphatics were o f any prognostic significance.
3. There was a significant statistical interaction between MET and HGF, as judged by discriminant 
analysis and by analysis o f variance and covariance. In other words, the combined effect o f the two 
was greater than the sum o f their individual effects.
4. When this interaction was included in our statistical models, either in the discriminant analysis or in 
the analysis o f variance and covariance, the direct effect o f MET became statistically insignificant. In 
other words, the effects o f  MET could be attributed entirely to the fact that its presence enhanced the 
influence o f HGF. There was no evidence that MET had any effect independent o f HGF,
5. The converse was not true: in other words, HGF appeared to be o f prognostic significance even when 
MET was apparently absent from the tumour, as judged by our assay. However, it is possible that 
with a more sensitive MET assay we might find that some o f our apparently MET-negative tumours 
do in fact contain some MET-positive cells. It is still possible therefore that the influence o f HGF 
may depend on the presence o f  MET.
6. The most significant o f all the prognostic indicators was HGF.
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Appendix 3
HGF/SF levels, % tumour vascular volume (%TVV), microvessel density (MVD) 
and KI-67 index in 73 patients with breast cancer.
Number MVD % TW KI-67% HGF/SF
96 37 4.1 5 66
137 69 4.7 5 510
145 41 3.9 20.5 252
151 97 10.3 22 558
154 39 3.8 5 62.4
165 111 10.2 32 832
171 76 5.8 7 95
206 89 6.6 20 58
213 115 15 5 ?
217 123 9.8 5 60
220 119 7.1 5 320
241 43 2.9 4 152
248 74 5.8 17 440
256 49 3.4 5 331
257 75 3.4 24 231
260 85 3.4 18 315
261 83 7.7 7 552
272 64 6.5 28 603
275 43 4 26 729
289 63 5.9 12 255
292 82 2 25 ?
293 48 5 25 163
294 103 6.1 24 168
296 109 9.2 18 595
300 63 4.4 28 441
306 57 5.3 13 84
310 37 3.1 34 184
313 119 5.2 59 233
319 121 11.1 23 374
330 74 5.1 26 100
334 30 5.4 16 370
372 55 6.5 16 420
373 41 8.9 46 1045
374 83 3.3 6 911
377 72 9.4 30 491
379 44 3.8 4 148
383 45 5 20 324
396 77 5.6 19 406
400 58 6.4 36 350
407 32 3.5 11 243
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Number MVD % TW KI-67% HGF/SF
410 173 13.9 33 620
417 46 5.8 14 588
425 157 12.5 32 995
433 53 4.5 8.8 473
436 91 4.8 15 185
437 91 9 2 465
442 123 7 15 475
446 84 4.3 19 330
451 58 3.5 5 129
455 47 3.4 11 120
462 36 5.3 6.8 84
474 111 4.9 5.6 132
475 ? ? 19.5 1604
477 80 7.2 5 396
478 72 8.1 29 677
489 96 6.2 13.5 78
494 88 ^ 4.1 ? 319
503 229 10.5 6.5 621
505 85 3.9 34 530
511 49 4.5 25 393
512 148 6.4 22 513
515 45 4.8 11 456
516 28 3 25 383
517 60 5.1 13 ^ 345
522 142 9.1 16 798
529 82 5.1 38 427
531 122 ^ 10.9 20 462
533 87 11.7 50 915
547 60 5.7 42 135
560 156 10.6 24 310
561 60 6.3 20 60
565 166 6.6 36 279
578 82 6.7 17 297
Key
HGF/SF ng/lOOmg total protein.
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